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ABSTRACT 
 
 
SHANKARI NARASIMHA SOMAYAJI.  RANK-L expression in Staphylococcus 
aureus- induced osteomyelitis, therapeutic intervention using nanotechnology and use of 
UV-killed bacteria as an osteoconductive coating for biomaterials.  (Under the direction 
of DR. MICHAEL C. HUDSON) 
 
 
 Staphylococcus aureus is responsible for approximately 80% of all cases of 
human osteomyelitis. RANK-L is an essential signal produced by osteoblasts and is 
required for full osteoclastic differentiation. PGE2 - induced bone resorption involves 
both inducible cyclooxygenase (COX-2), as well as RANK-L. Our st dies show that 
during infection with S. aureus, osteoblasts increase RANK-L and PGE2 secretion. 
Through the use of NS-398, a specific COX-2 inhibitor, we show that when PGE2
production is inhibited, RANK-L production is decreased. In the current study, we also 
demonstrate that effective killing of intracellular S. aureus is possible by treating the 
infected osteoblasts with nanoparticles loaded with nafcillin antibiotic.  
           While titanium alloys are the preferred material of choice for orthopaedic 
implants, they do not mediate osseointegration (intimate apposition of bone to the 
implant surface). Enhancement of titanium (Ti) based biomaterials is therefore necessary 
to increase the functional lifespan of an implant. S. aureus can bind to biomaterials 
directly and also attach efficiently to osteoblasts. Moreover, as UV-killed S. aureus does 
not stimulate immune modulator expression, we investigated whether UV-killed bacteria 
could serve as a novel osteoconductive coating on Ti alloy surfaces. Our in vitro data 
demonstrate that osteoblast adhesion and matrix synthesis was enhanced on Ti surfaces 
coated with bacteria compared to uncoated surfaces. In vivo, the osteoconductivity of S. 
aureus-coated implants was increased at 8 weeks compared to the uncoated implants. 
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INTRODUCTION 
 
 
Staphylococcus aureus is a gram-positive bacterium that causes serious 
community-acquired and nosocomial infections (33). The range of disease cau ed by S. 
aureus is broad and includes septic shock, skin infections, endocarditis and osteomyelitis 
(3). S. aureus is the most common nosocomial pathogen encountered in the United States 
and the incidence of nosocomial S. aureus-induced disease has increased dramatically in 
recent years (3, 6, 22). Diseases caused by antibiotic-resistant str i s of S. aureus are a 
worldwide epidemic and are necessitating the development of novel therapies for their 
treatment (4, 33). Once considered an extracellular pathogen, recent evidenc , both in 
vitro and in vivo, indicates that S. aureus has the ability to invade osteoblasts and persist 
intracellularly, therefore escaping host humoral immune responses (3, 33). Additional 
studies have shown that S. aureus, once internalized, can escape the host endosome and 
gain access to the cytoplasm (8). The persistence of intracellul r S. aureus is the first 
indication that the survival of these bacteria inside the osteoblasts could be involved in 
bone infection. 
Staphylococcus aureus and osteomyelitis. 
S. aureus is responsible for approximately 80% of all osteomyelitis cases (50).  
Osteomyelitis is an infection of bone that results from hematogenous seeding, spread of 
infection from a contiguous area such as the skin adjacent to the wound, or surgical or 
traumatic inoculation of bacteria into bone (26). The disease can be acute or chronic with 
sporadic recurrence (3, 59). The current treatment for osteomyelitis is often traumatic, 
expensive, and leads to further selection of antibiotic-resistant si s of S. aureus.  In 
many cases it is necessary that infected bone is debrided, tissues are reconstructed and 
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long-term antibiotic therapy is used (59). The pathogenesis of S. aureus-induced 
osteomyelitis is poorly understood. Elucidating the mechanisms by which S. aureus 
induces osteomyelitis could lead to a better understanding of the disease, its progression, 
and development of new treatments. 
Role of MSCRAMMs in mediating cell adherence and internalization. 
Staphylococcus aureus is an extremely capable bone pathogen and is a common 
cause of bone and joint infections in humans because it possesses sveral cell-surface 
adhesion molecules that facilitate its binding to bone matrix. Binding involves a family of 
adhesins that interact with extracellular matrix components and these adhesins have been 
termed microbial surface components recognizing adhesive matrix molecules 
(MSCRAMMs). MSCRAMMs recognizing proteins such as collagen, bone sialoprotein, 
fibronectin, and fibrinogen mediate adherence of S. aureus to bone and biomaterials 
coated with host proteins (39). S aureus can bind to cells either directly by utilizing 
MSCRAMMs or via bridging ligands, proteins which have affinity for both host cell 
receptors and MSCRAMMs (24, 62). Amongst all MSCRAMMs, Fibronecti -binding 
proteins (FnBPs) are critically important for adherence and invasion of S. aureus of 
osteoblasts. A bridging model has been proposed to explain interaction of S. aureus with 
osteoblasts where fibronectin is bound by FnBPs as well as host cell integrins. Integrins 
are αβ-heterodimeric cell membrane receptors which mediate adhesion between cells and 
components of extracellular matrix which is subsequently known to induce signal 
transduction, tyrosine kinase activity, and cytoskeletal rearrangement (23, 24). 
Specifically, distinct peptide sequences such as Arg-Gly-Asp motif (RGD) from adhesive 
proteins interact with integrin cell membrane receptors (30). At least six bone- related 
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proteins; fibronectin, bone sialoprotein, collagen, osteopontin, thrombospondin and 
vitronectin are known to contain the RGD adhesive sequence (60). α5β1 integrin, the most 
predominant integrin found on osteoblasts, binds to Fibronectin (Fn) with high specificity 
while α2β1 integrin binds to collagen and laminin in addition to binding to Fn (18). 
Bone remodeling and regulatory factors involved in the process. 
Skeletal structure is continually adapting to metabolic and mechanical demands 
(79).  Bone remodeling is a continuous, coordinated equilibrium between bone synthesis 
and bone resorption (71), and two principal cell populations are responsible for the 
continual process.  Osteoclasts derive from myeloid precursors and drive the resorption 
of bone by acidification and release of lysosomal enzymes.  Conversely, osteoblasts 
derive from a mesenchymal bone marrow precursor and produce components f bone, 
principally type I collagen.  Osteoblasts also catalyze the calcification process and 
produce factors which serve to modulate the activity or formation of osteoclasts (11). 
Perturbations in inflammatory cytokines, growth factors, and hormones cau e an 
imbalance between osteoblast and osteoclasts activities and result in skeletal 
abnormalities such as decreased bone mineral density, reduced bone strength, f actures, 
hypercalcemia, osteopetrosis, and osteoporosis (9, 78). 
Receptor Activator of NF-κB Ligand: Recent studies have revealed key molecules 
involved in the communication between osteoblasts and osteoclasts. Receptor Activator 
of NF-κB Ligand (RANK-L) is a transmembrane molecule belonging to the TNF ligand 
superfamily that is expressed in lymphoid tissue and trabecular bone (56).  Murine 
RANK-L is a 316 amino acid, 45kDa protein that shares 83% sequence homology with 
human RANK-L.  The protein contains a ligand-binding region in its C-erminal half, and 
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has a transmembrane domain.  It has also been proposed that RANK-L can be cleaved 
into a soluble form.  Binding of RANK-L to RANK, found on osteoclasts, triggers 
intricate and distinct signaling cascades that control lineage commitment and activation 
of osteoclasts (78).  RANK-L is thought to be the essential and final common signal 
required both in vitro and in vivo for full osteoclastic differentiation from multipotential 
hematopoietic precursor cells into mature multi-nucleated bone-resorptive osteoclasts 
(43, 44). 
Osteoprotegerin and Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand: 
Osteoprotegerin (OPG), produced and secreted by osteoblasts, is a negative regulator of 
osteoclast formation (64, 83).  OPG is a member of the TNF receptor supe family and is 
secreted as a disulfide-linked 110 kDa homodimer (47, 64, 77).  The expression of OPG 
is positively (e.g. TGFβ, IL-1, TNF, estrogen) and negatively (e.g. PGE2 and 
glucocorticoids) regulated by a wide array of factors.  OPG represents an endogenous 
receptor antagonist that can bind to RANK-L and neutralize the biologic effects of 
RANK-L. Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand [TRAIL] (64), is 
another key molecule produced by osteoblasts.  Alexander et al demonstrated that when 
osteoblasts are infected with S. aureus, TRAIL expression is increased (2).  TRAIL has 
numerous receptors including, R1, R2, R3, R4, and OPG.  Since TRAIL expression i  
increased by S. aureus-infected osteoblasts and OPG is known to bind both TRAIL and 
RANK-L, competition may limit the amount of OPG available to block the interaction 
between RANK-L and RANK during infection of osteoblasts by S. aureus. 
Okahashi et al demonstrated that normal mouse osteoblasts infected with 
Streptococcus pyogenes increase expression of RANK-L mRNA and protein (56).  These 
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data indicate that when challenged with intracellular bacteria, osteoblasts increase 
RANK-L expression, suggesting one possible mechanism whereby S. aureus-infected 
bone tissue undergoes altered remodeling. We therefore hypothesize that RANK-L 
mRNA and protein expression is induced during normal mouse osteoblast infection 
with S. aureus at increasing Multiplicities of Infection (MOI) and at variou s time 
points. 
Role of prostaglandin E2 in RANK-L production: RANK-L expression in osteoblasts is 
up-regulated by pro-resorptive hormones and cytokines, such as 1α, 25-dihydroxyvitamin 
D3 (1α, 25(OH)2D3), parathyroid hormone (PTH), prostaglandin E2 (PGE2), and 
interleukin (IL)-1 (37, 38, 80, 83).  Prostaglandin E2 (PGE2) is produced in bone mainly 
by osteoblasts and acts as a potent stimulator of bone resorption (58, 61, 70).  It has also 
been reported that PGE2 induces osteoclast formation in mouse bone marrow cultures and 
stimulated bone resorption in mouse calvarial cultures (1, 15, 73).  PGE2 synthesis is 
regulated by three metabolic steps: the release of arachidonic acid from the membranous 
phospholipids by phospholipase A2 (PLA2), the conversion of arachidonic acid to PGH2 
by cyclooxygenase (COX), and the synthesis of PGE2 by PGE synthase (16, 41, 46, 54, 
63, 65, 75) .  Although both constitutive COX (COX-1) and inducible COX (COX-2) are 
expressed in mouse osteoblasts, the expression of COX-2 is markedly induced by several 
bone-resorbing factors such as IL-1 and Il-6.  Bost et al. (13, 25) reported that S. aureus 
infection induces IL-6 and IL-12 production by osteoblasts.  Stimulation of RANK-L, IL-
6, and IL-12 , are important events in bone destruction (43-45, 70, 74, 76). IL-6 can 
directly or indirectly modulate the activity of bone-resorptive oste clasts (42, 69), 
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possibly through the induction of PGE2 , and in turn RANK-L.  The addition of NS-398, a 
selective inhibitor of COX-2, was shown to inhibit IL-1-induced PGE2 synthesis (15, 73).   
Since it has been determined that PGE2 can up-regulate RANK-L (37, 38, 80, 83), 
we propose that PGE2 production by S. aureus-infected osteoblasts will be increased 
and that inhibition of PGE2 by the specific COX-2 inhibitor, NS-398 will result in 
decreased levels of PGE2 and RANK-L by infected osteoblasts. Based on the results of 
these proposed studies, agents that inhibit COX-2 or block RANK-L productin ould 
potentially ameliorate bone loss.  
Treatment of osteomyelitis. 
Surgical intervention as well as antibiotic therapy using cephalosporins and 
penicillins remains the most effective means of treatment for this disease (51). However, 
osteomyelitis cases caused by S. aureus are especially chronic in nature and recalcitrant 
to therapy. In addition, the effectiveness of traditional antibacterial agents is becoming 
increasingly limited as the prevalence of methicillin-resistant S. aureus (MRSA), has 
increased sharply in recent years. The wide array of virulence factors in S. aureus, 
including secreted products for host damage and immune avoidance, coupled with its 
ability to invade and reside inside osteoblasts using cell surface adherence factors, can 
protect these bacteria from host defence mechanisms and antibiotics which can account 
for the persistence of disease despite what may be considered adequate surgical and 
antibiotic management (19).  
Poly (lactide-co-glycolide) (PLGA) based nanoparticles for antibiotic delivery: The 
biodegradability and biocompatibility of polymers such as poly (lactic acid) (PLA), poly 
(lactide-co-glycolide) (PLGA), and polyanhydrides (PAH) as well as their use as drug
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delivery systems have been clearly demonstrated (28, 29, 66, 67). One of the advantages 
of these systems for drug delivery is reduction in systemic complications and allergic 
reactions due to the feasibility of delivering the drug locally (14). In addition, no follow-
up surgical interference is required once the drug supply is depleted (53). Lastly, 
biodegradation occurs by simple hydrolysis of the ester backbone in aqueous 
environments such as body fluids and the degradation products are then metabolized to 
carbon dioxide and water.  We propose to use biodegradable polymer nanoparticles 
loaded with nafcillin that can penetrate osteoblasts infected with S. aureus and 
deliver the antibiotic intracellularly. Nafcillin is an amphiphillic pencillin (32) which 
can effectively kill S. aureus but cannot enter eukaryotic cells in its native form. A novel 
approach of using polymer nanoparticles loaded with an antibiotic would ensure that 
these particles diffuse across the osteoblast cell membrane thereby effectively delivering 
the drug that can target both intracellular and extracellular bacteria. In addition, the drug 
can be delivered topically rather than systemically which would reduce the emergence of 
antibiotic resistant strains.  
Composition of bone. 
Bone is an anisotropic and dynamic tissue consisting of cells (osteoblasts and 
osteoclasts), connective tissue (primarily type 1 collagen), and mi erals (hydroxyapatite).  
Osteoblasts form a bone matrix (the osteoid) that later becomes mineralized. The 
extracellular matrix (ECM) secreted by osteoblasts is approximately 90% collagen and 
10% non-collagenic proteins such as osteocalcin, osteonectin, sialoproteins, 
proteoglycans, osteopontin, and fibronectin (68). These extracellular matrix proteins can 
contribute to both bone formation and homeostasis. For instance, fibronectin is important 
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for cell attachment whereas osteocalcin and osteopontin serve as foci for deposition of 
mineral component. Successful communication between cells and the ECM is mediated 
by the family of cell surface receptors called integrins that stimulate signal transduction 
pathways and mediate osteoblast adhesion, spreading, cell differentiation and bone 
morphogenesis (31, 34, 57). Specifically, integrin activation induces expression of 
osteoblast specific transcripts such as osteocalcin and type I collagen and is required for 
differentiation of osteoblast precursors (82).  
Bone-associated biomaterials and osseointegration. 
Artificial joints and orthopedic implants are used to repair or estore function to 
damaged and diseased tissue. Following insertion, the host response to implants involves 
a series of events, both at a cellular and molecular level, which ideally should result in 
osseointegration. Osseointegration is desirable because it represents formation of an 
appropriate interface and provides a functional connection between the implant and bone 
(5). Of the various implant materials, titanium (Ti) and cobalt-chromium (Co-Cr) alloys 
as well as bioactive ceramics such as calcium phosphate, principally hydroxyapatite, and 
bioglass are most commonly used (49). However, Titanium alloys such as Ti-6Al-4V are 
the preferred material of choice for orthopedic applications as it offers excellent 
biocompatibility on account of the interaction of its spontaneously formed oxide layer 
with the biologic fluids, resistance to corrosion and excellent mechani al properties (52). 
However, a major disadvantage of titanium alloys as a biomaterial is that they are 
relatively bio-inert and do not facilitate or mediate osseointegra ion which is intimate 
apposition of bone to the implant surface (20). As a result, the functional lifespan of 
artificial prostheses is estimated at about 15 years which makes them unsuitable for 
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active and younger patients (52). Enhancement of biomaterials is therefore necessary in 
order to increase the implant success rate and extend their functional lifespn. 
Modification of implant surfaces to enhance osseointegration. 
A number of techniques have been employed to enhance such biomaterials, 
including alteration of surface roughness, wettability, porosity, and hydrophobicity in an 
attempt to enhance osseointegration and mediate proper interface formation (5, 52, 81).  
Some of these strategies include modulating the implant surface by applying coatings of 
either extracellular matrix (ECM) components such as fibronecti, collagen, 
hydroxyapatite (HAP), bone sialoprotein (BSP) or cell adhesion peptides; Arg-Gly-Asp 
(RGD) or osteotropic growth factors such as Bone morphogenetic proteins; BMPs and 
Transforming growth factor-beta; TGF-β (17, 21, 27, 48, 55). However, there are still 
long-term complications and limitations associated with these methods such as high 
temperatures needed for coating in case of HAP which in turn alter bo h mineral as well 
as metal structure, variable thickness of deposited coatings a d their subsequent 
dissolution from the substrates (7, 10, 27, 72). In addition, short half-life of 
osteoinductive growth factors along with their high concentrations locally n cause 
ectopic bone formation which is concerning in their applications. Lastly, while the 
coating treatments enhanced binding of osteoblasts to implant surfaces, cellular functions 
of osteoblasts failed to increase subsequently.  
Binding of S. aureus to biomaterials. 
For the clinical success of implants, anchorage-dependent cellssuch as 
osteoblasts must first successfully adhere to the implant surface in order to perform 
subsequent cellular functions such as proliferation and deposition of a mineralized 
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extracellular matrix (ECM) (5). In this context, it has been shown extensively that S. 
aureus can bind to biomaterials directly (35, 36). Following insertion, bacteria adhere to 
biomaterials coated immediately with host plasma constituents includ g fibronectin and 
fibrinogen and this adherence is mediated by MSCRAMMs, particularly FnBPs (39). As 
described earlier, S. aureus, both live and UV-killed, can also bind efficiently to 
osteoblasts and then induce signal transduction, tyrosine kinase activity, and cytoskeletal 
rearrangement (23, 24, 40). Lastly, while viable S. aureus cells are potent inducers of 
immune modulator expression by osteoblasts such as interleukin (IL)-6, -12 and 
monocyte chemoattractant protein (MCP-1), UV-killed S. aureus does not induce 
significant expression of such molecules (11-13). All of the above present an intriguing 
combination of properties that can be utilized in a novel coating of implant materials 
which can solicit osteoblast adhesion specifically around an implant. Potentially, an 
increase in osteoblast recruitment, a necessary pre-requisite for subsequent cell functions 
on biomaterials, can result in enhanced synthesis of an extracellulr matrix on bone-
biomaterial interface which can lead to enhanced osseointegration. Therefore, as UV-
killed S. aureus can tenaciously bind biomaterials and effectively colonize bone 
which can initiate cell-signaling cascades that can potentiate osteogenesis, we 
propose to examine the use of S. aureus as an effective osteoconductive coating for 
bone-associated biomaterials. 
In summary, the current study investigates the expression of RANK-L and PGE2 
by S. aureus- infected osteoblasts and also evaluates the therapeutic use of nafcillin-
loaded nanoparticles in targeting both intracellular and extracellular bacteria in an in vitro 
model of osteomyelitis. We also examined the use of UV-killed S. aureus as a bioactive 
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coating for implants both in vitro and in vivo. The dissertation is divided into four 
sections with one section dedicated to the data relevant to each corresponding objective 
as described above. Each section is in turn comprised of an introduction, materials and 
methods, results, and discussion chapter. A summary section on the entirety of this 
research is presented at the end of the dissertation. 
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CHAPTER 1: INTRODUCTION 
 
 
Osteomyelitis is a severe infection of bone tissue that results in progressive 
inflammatory destruction of bone (40). The gram-positive organism, Staphylococcus 
aureus, is the most common causative agent of osteomyelitis, accounting for 
approximately 80% of all human cases (25). It is often necessary th t infected bone be 
debrided, tissues reconstructed and long-term antibiotic therapy utilized (17).  The 
current treatment for osteomyelitis is often traumatic, expensiv , and leads to further 
selection of antibiotic-resistant stains of S. aureus.  The growing incidence of antibiotic-
resistant S. aureus strains can explain the recurrent attacks of osteomyelitis in patients 
undergoing therapy. In addition, the pathogenesis of S. aureus-induced osteomyelitis is 
poorly understood.  Elucidating the mechanisms by which S. aureus induces 
osteomyelitis could therefore lead to a better understanding of the disease, its 
progression, and development of new treatments. 
Bone remodeling is a continuous, coordinated equilibrium between bone synthesis 
and bone resorption and two cell populations are responsible for the continual process 
(21). Osteoclasts drive the resorption of bone by acidification and release of lysosomal 
enzymes while osteoblasts produce components of the bone matrix, principally ty e I 
collagen.  Osteoblasts also produce factors which serve to modulate the activity or 
formation of osteoclasts (1).   One such key molecule produced by osteoblasts is receptor 
activator of NF-κB ligand (RANK-L), which on binding to RANK, found on osteoclast 
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precursors, triggers intricate and distinct signaling cascades that control lineage 
commitment and activation of osteoclasts (52).  RANK-L is therefore thought to be the 
essential and final common signal required both in vitro and in vivo for full osteoclastic 
differentiation from multipotential hematopoietic precursor cells into mature multi-
nucleated bone-resorptive osteoclasts (22, 23).  Thus, osteoblasts can regul te both net 
bone formation as well as resorption. 
Prostaglandin E2 (PGE2) is produced in bone mainly by osteoblasts and acts as a 
potent stimulator of bone resorption by inducing osteoclast formation in both mouse bone 
marrow cultures and calvarial cultures (1, 7, 35, 39, 45, 47).  PGE2 synthesis is regulated 
by three metabolic steps: the release of arachidonic acid fromthe membranous 
phospholipids by phospholipase A2 (PLA2), the conversion of arachidonic acid to PGH2 
by cyclooxygenase (COX), and the synthesis of PGE2 catalyzed by PGE synthase (9, 19, 
24, 32, 41, 43, 49).  Although both constitutive COX (COX-1) and inducible COX 
(COX-2) are expressed in mouse osteoblasts, the expression of COX-2 is markedly 
induced by several proinflammatory cytokines such as IL-6.  Bost et al. (5, 11) have 
reported that S. aureus-infected osteoblasts produce high levels of IL-6 which have been 
shown to modulate the activity of bone-resorptive osteoclasts either d rectly or indirectly 
(20, 44).  It has also been determined that PGE2 can up-regulate RANK-L expression in 
osteoblasts (15, 16, 53, 56).  
 Bacterial pathogens can stimulate osteoclastogenesis which can potentiate bone 
resorption leading to bone destruction (29). Okahashi et al (34) have also  demonstrated 
that normal mouse osteoblasts infected with Streptococcus pyogenes increase expression 
of RANK-L mRNA and protein. In addition, elevated levels of RANK-L have been 
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detected in the bone lesions of mandibular osteomyelitis (31). We ther fore propose that 
following an intracellular challenge with S. aureus, osteoblasts can increase RANK-L 
expression which could stimulate osteoclast activity and thereby potentiate the bone loss 
that occurs in S. aureus-infected bone tissue. The current study investigates RANK-L 
mRNA and protein expression during normal mouse osteoblast infection with S. aureus. 
Such a proposed upregulation of RANK-L from infected osteoblasts could be mediated 
either directly or indirectly. Since it has been determined that PGE2 can up-regulate 
RANK-L, we propose in the current study that PGE2 production by S. aureus-infected 
osteoblasts will be increased and that inhibition of PGE2 by the specific COX-2 inhibitor, 
NS-398 will result in decreased levels of PGE2 and RANK-L by infected osteoblasts. 
 
 
 
 
 
 
 
CHAPTER 2: MATERIALS AND METHODS 
 
 
Bacterial strains:  
Staphylococcus aureus strain UAMS-1 (ATCC 49230) is a human osteomyelitis 
clinical isolate (14). Staphylococcus carnosus (ATCC 51365) is a nonpathogenic species 
with reduced ability to invade osteoblasts (11). Strains N1, N2, N3, N4 and N5 are 
Staphylococcus aureus nasopharyngeal isolates kindly provided by Dr. Vance G. Fowler, 
Jr. (Duke University Medical Center).   
Normal mouse osteoblast cell culture: 
 Primary osteoblasts were isolated from mouse neonatal calvariae by sequential 
digestion with collagenase and protease according to a method previously described for 
chick embryos (37). The periostea were removed, the frontal bones wer harvested free 
of the suture regions, and the bones were incubated for 10 min at 37°C in 10 ml of 
digestion medium containing collagenase (375 U/ml, type VII; Sigma Chemical 
Company, St. Louis, MO) and protease (7.5U/ml; Sigma). Cells released during an initial 
7 min digestion were discarded. Ten milliliters of fresh digeston medium was added, and 
incubation continued for another 20 min. Cells were harvested by centrifuga ion and 
rinsed three times in 25 mM HEPES- buffered Hanks’ balanced salt solution (pH 7.4; 
HBSS). The digestion step was repeated twice, and the three cell isolates were pooled in 
mouse osteoblast growth medium (OBGM) consisting of Dulbecco’s modified eagle 
medium containing 25 mM HEPES, 10% fetal bovine serum (Atlanta Biologicals, GA), 2 
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g of sodium bicarbonate per liter, 75 mg of glycine/ml, 100 mg of ascorbic acid, 40 ng of 
vitamin B12/ml, 2 mg of p-aminobenzoic acid/ml, 200 ng of biotin/ml, and penicillin (100 
U/ml)-streptomycin (100 µg/ml)-amphotericin B (25 µg/ml) (pH 7.4) (36). Osteoblasts 
were seeded in six-well polystyrene dishes and incubated at 37°C in a 5% CO2 
atmosphere until they reached confluence (6-7 days).  
Invasion assay:  
The invasion assay with live or UV-killed S. aureus strain UAMS-1, live S. 
carnosus, or live nasopharyngeal isolates was performed as previously described (11, 12). 
Bacteria were grown overnight (16 h) in 5 ml of tryptic soy broth in a shaking water bath 
at 37°C. The bacteria were harvested by centrifugation for 10 min at 4,300 × g at 4°C and 
washed twice. The pellets were then resuspended in 5 ml of growth mediu  lacking 
antibiotics/antimycotics (Abx-Amx). Confluent cell layers of osteoblasts were washed 
three times to remove the growth medium. The cultures were then inf cted at a 
multiplicity of infection (MOI) of 25:1 or 75:1 with S. aureus strain UAMS-1, or with S. 
carnosus, UV-killed S. aureus or the nasopharyngeal isolates at a MOI of 25:1 in 4 ml of 
growth medium lacking Abx-Amx. Following a 45-minute infection period, infected cell 
cultures were washed three times and incubated for 1 h in growth medium containing 25 
µg of gentamicin/ml to kill the remaining extracellular bacterial cells. The osteoblast 
cultures were washed and subsequently lysed at different time points by the addition of 
1.2 ml of 0.1% Triton X-100 (Fisher Biotech, N.J.) with incubation for 5 min at 37°C.  
Quantitative real-time polymerase chain reaction: 
 To quantify RANK-L mRNA, real-time PCR was performed using a Roche 
LightCycler 2.0 with SYBR Green reagent (QIAGEN, CA) according to the 
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manufacturer’s instructions.  Amplicons of RANK-L and G3PDH were us d to develop a 
standard curve.  Samples were subjected to 40 cycles of amplification onsisting of 95°C 
for 15 s followed by 53°C for 20 s.  Each assay was normalized to G3PDH mRNA.  PCR 
primers were derived from published sequences (IDT, IA.) (34).  Positive and negative 
strand primers were as follows: 
RANK-L (89 bp) 
5’-TACTTTCGAGCGCAGATGGAT-3’      
5’-ACCTGCGTTTTCATGGAGTCT-3’ 
G3PDH (63 bp) 
5’-AACTACATGGTCTACATGTTCCA-3’    
5’-CCATTCTCGGCCTTGACTGT-3’ 
Protein isolation: 
 Osteoblasts were isolated and seeded at 106 cells per well in six-well plates and 
infected once the cells had reached confluence (6-8 days).  Following a 45-minute 
incubation +/- bacteria and 1 hour treatment with 25 µg/ml gentamicin sulfate, total 
protein was isolated from the osteoblasts at 0, 6, and 24 hours using Tissue Protein 
Extraction Reagent (T-PER) (PIERCE, IL) with additional protease inhibitors, aprotinin 
(2 µg/ml) and lupeptin (2.5 µg/ml) (Sigma Chemical Company, MO).  Two hundred µl of 
T-PER was added to each well at the appropriate time point and cells were removed from 
the culture plates with a cell scraper (Costar).  Samples wre collected in 1.5 ml 
microcentrifuge tubes and then centrifuged at 10,000 x g for 2 minutes to pellet cell 
debris.  Supernatants were collected and placed in fresh tubes and stored at -80°C. 
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Inhibitor study:  
Osteoblasts were isolated and cultured in six-well plates as previously described.  
Forty-eight hours prior to infection, cells were either treated with 0.025% 
dimethylsulfoxide (DMSO) or 20µM NS-398 (Cayman Chemicals, MI), a specific COX-
2 inhibitor, dissolved in DMSO at an optimal dose that was previously determined to 
provide inhibition of COX-2 (6, 57).    Following the 48 hour treatment, cells were rinsed 
one time with osteoblast growth medium (OBGM) containing no Gentamicin Sulfate or 
Amphotericin B.  One ml of OBGM, containing no Gentamicin Sulfate or Amphotericin 
B and containing either DMSO or NS-398, was then added to each appropriate well.  The 
osteoblasts were either uninfected (MOI 0) or were infected with the bacterial strains 
noted above using the method previously described.  Following the 45-minute incbation 
+/- bacteria, each well was rinsed one time with OBGM.  One ml of fresh media, 
containing either DMSO or NS-398 and 25 µg/ml of Gentamicin, was then added to each 
well.  Cells were then incubated for 1 hour at 37°C in a 5% CO2 atmosphere to allow 
remaining extracellular bacteria to be killed.  Following the 1 hour incubation period, 
protein samples were isolated as previously described (time 0). Samples were also 
isolated at 6 hours and 24 hours following time 0.  In addition, culture supernatants were 
collected and stored at -80°C.   
Quantification of RANK-L protein and prostaglandin E2:  
Using protein samples collected as previously described, mouse 
TRANCE/TNSF11/RANK ligand ELISA (R&D Systems, Minneapolis, MN) was used to 
detect the levels of RANK-L in osteoblast whole cell extracts. Prostaglandin E2 correlate-
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enzyme immunoassay (EIA) (Assay Designs, MI) was performed on the cell culture 
supernatents following the manufacturer’s instructions.    
Statistical analysis: 
 Data were analyzed using a two-way analysis of variance followed by the Tukey-
Kramer multiple comparison analysis.  Results are presented as the mean ± standard 
error.  For all tests p < 0.05 was considered significant. 
 
 
 
 
 
 
 
 
CHAPTER 3: RESULTS 
 
 
Induction of RANK-L mRNA expression in osteoblasts following exposure to 
bacteria:   
Staphylococcal osteomyelitis is associated with increased osteoclast activity and 
RANK-L is a key factor required for osteoclastogenesis (22, 23, 45, 56).  Therefore, it is 
important to determine whether osteoblasts infected with S. aureus produce RANK-L and 
if the levels of RANK-L increase in a time- and dose-dependent manner.  Quantitative 
analysis by real-time RT-PCR demonstrated that the RANK-L expression in osteoblasts 
infected with S. aureus strain UAMS-1 (75:1 MOI) was tenfold greater than RANK-L 
expression in uninfected cells at 4 hours following infection (Figure 1).  RANK-L mRNA 
expression by osteoblasts also increases in a dose-dependent manner.  In addition, we 
show that there was a time-dependent increase in RANK-L mRNA in Figure 1 with the 
expression of RANK-L mRNA by infected cells being tenfold greater than the expression 
in the uninfected controls at 4 hours. 
 To confirm that the changes in RANK-L mRNA result in corresponding protein 
expression, cell associated RANK-L was measured by specific capture ELISA. As shown 
in Figure 2, there was a time- and dose-dependent response to S. aureus strain UAMS-1.  
At 24 hours and an MOI of 75:1, there was a 2.5 fold increase in RANK-L protein 
compared to the control. Although the documented effects of RANK-L have been shown 
to be mediated by the membrane-bound form, we also measured the levels of soluble 
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RANK-L as well and found its levels to be undetectable (data not sh wn). Osteoblasts 
infected with S. carnosus and UV-killed S. aureus strain UAMS-1 demonstrate the same 
levels of RANK-L protein expression as uninfected osteoblasts (Fig 2). Additionally, 
osteoblasts infected with S. aureus nasopharyngeal isolates N3 and N4 induce RANK-L 
production at levels similar to strain UAMS-1 at 0 hour. Strains N4 and N3 sustain this 
increased RANK-L expression following 6 and 24 hours of incubation, respectively.  
Induction of prostaglandin E2 expression by osteoblasts following exposure to 
S. aureus:  
Choi et al (8) demonstrated that PGE2 is a main mediator in RANK-L dependent 
osteoclastogenesis induced by several periodontal pathogens. Therefore, it is possible that 
RANK-L production in osteoblasts infected with S. aureus involves a PGE2-dependent 
mechanism. The current study examined levels of PGE2 following infection of 
osteoblasts by S. aureus.  Figure 3 demonstrates that PGE2 is up-regulated by S. aureus 
strain UAMS-1-infected osteoblasts at all time points examined.  Although there is no 
significant difference between infection at the 25:1 and 75:1 MOI, there is a significant 
difference in PGE2 expression between S. aureus strain UAMS-1-infected and uninfected 
osteoblasts.  Figure 3 also shows that the increase in levels of PGE2 occurs early 
following S. aureus infection and remains at an elevated level throughout the 24 hour 
duration of the experiment. PGE2 expression in response to UV-killed S. aureus strain 
UAMS-1- or S. carnosus-infected osteoblasts is not significantly different than that 
observed from uninfected osteoblasts (Fig 3). Although S. aureus nasopharyngeal isolates 
N1-N5 significantly increase PGE2 expression at time 0, PGE2 levels following 6 and 24 
hours of infection are comparable to uninfected osteoblasts.  
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Prostaglandin E2 production mediates S. aureus-induced increases in RANK-L 
production by osteoblasts:   
 
One of the steps in the PGE2 synthesis pathway involves the conversion of 
arachidonic acid to PGH2, which is then metabolized to PGE2, by cyclooxygenase 
enzyme (COX). The addition of NS-398, a selective inhibitor of COX-2, inhibits IL-1-
induced PGE2 synthesis (7, 47).  Therefore, in the current study, it is hypothesized that 
inhibition of COX-2 by NS-398 will result in decreased levels of PGE2 production by S. 
aureus-infected osteoblasts.  Figure 4 demonstrates that NS-398 significantly attenuates 
PGE2 production in both uninfected and S. aureus-infected osteoblasts.  Infected control 
cells treated with DMSO show the same dose-response to S. aureus strain UAMS-1 seen 
in Figure 3.   
 Since it is known that PGE2 up-regulates RANK-L, we also examined the effects 
of NS-398 on RANK-L expression by S. aureus-infected osteoblasts.  When infected 
osteoblasts were treated with NS-398, RANK-L levels were att nuated; indicating S. 
aureus-induced PGE2 plays a role in RANK-L expression by infected cells (Figure 5).  
 
 
 
 
 
 
CHAPTER 4: DISCUSSION 
 
 
 Osteomyelitis is a disease associated with abnormal bone remodeling and bone 
resorption. The mechanisms responsible for such bone loss are largely unclear. The 
generation of proinflammatory cytokines and chemokines helps recruit immune cells, 
such as leukocytes, which could alter the balance between bone resorption and formation. 
Recent studies in our lab have demonstrated S. aureus-infected osteoblasts as a hitherto 
unrecognized source of soluble immune modulators both in vivo and in vitro (3-5, 27, 
28). Osteoblasts can also produce other soluble factors that can modulate the ctivity or 
formation of osteoclasts. RANK-L is one such key molecule that stimulates 
differentiation in osteoclasts and is an inducing agent involved in bone destruction (22, 
23, 45, 48, 56).  Following the binding of RANK-L to its receptor RANK on osteoclast 
precursors, the signal transduction can diverge into diverse pathways that can regulate 
distinct aspects of osteoclast functions (10, 17, 33, 38, 55).    
Bacterial pathogens can stimulate osteoclastogenesis, either directly or indirectly,  
which can potentiate bone resorption leading to bone destruction (29, 34). Ishida et al 
have recently shown elevated RANK-L expression in S. aureus-infected NRG cells, 
which is a fibroblast cell line that has osteoblast like features (18). Based on these 
findings, we undertook this study to evaluate the production of RANK-L from S. aureus- 
infected primary osteoblasts. Results outlined in Figures 1-2 demonstrate that viable S. 
aureus strain UAMS-1 is a potent inducer of membrane-bound, and not secreted, RANK-
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L mRNA and protein production by osteoblasts. In addition, UV-killed S. aureus strain 
UAMS-1 did not induce RANK-L expression, thus indicating that active bacteri l gene 
expression may be required for maximal RANK-L production. Similarly, S. carnosus, an 
invasion-deficient species, did not stimulate increased RANK-L expression. Although 
osteoblasts infected with S. aureus nasopharyngeal isolates N3 and N4 induce RANK-L 
expression comparable to expression from osteoblasts infected with the os eomyelitis 
clinical isolate UAMS-1 at time 0, and the strains maintain induction at 6 hours in one 
case and at 24 hours in the other, it is possible that strains N3 and N4 are capable of 
inducing osteomyelitis if they gain access to the bloodstream and subsequently to bone. 
The majority of the nasopharyngeal isolates are not capable of inducing RANK-L 
production. Taken together, these findings substantiate that live S. aureus is required for 
maximal RANK-L production from infected osteoblasts. An increase in RANK-L 
production by infected osteoblasts can further osteoclast differentiatio  nd activation 
which can potentiate the exacerbated bone destruction observed during osteomyelitis.   
 While RANK-L potentiates osteoclastogeneis, Osteoprotegerin (OPG), produced 
and secreted by osteoblasts, is a negative regulator of osteocla formation. Tumor 
Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL) (42), is another key 
molecule produced by osteoblasts which can bind to OPG.  Alexander et al (2) have 
demonstrated that when osteoblasts are infected with S. aureus, TRAIL expression is 
increased. Since OPG is known to bind both TRAIL and RANK-L, competition may 
limit the amount of OPG available to block the interaction betwen RANK-L and RANK 
during infection of osteoblasts by S. aureus.  Taken together, it is highly likely that the 
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increased levels of RANK-L contributes to the massive bone loss and aberrant bone 
remodeling associated with the pathology of staphylococcal osteomyelitis. 
We next attempted to delineate the mechanism involved in up-regulation of 
RANK-L expression in osteoblasts following exposure to S. aureus. Prostaglandin E2 
(PGE2) is produced in bone mainly by osteoblasts and acts as a potent stimulator of bone 
resorption (35, 39, 45). It has been demonstrated that PGE2 can mediate RANK-L-
dependent osteoclastogenesis in periodontal diseases (8). Furthermore, the production of 
PGE2 by osteoblasts is regulated by several cytokines and is also reported to induce 
osteoclast formation in mouse bone marrow cultures and stimulate bone resorption in 
mouse calvarial cultures (1, 7, 47). We therefore hypothesized that increased RANK-L 
expression in infected osteoblasts occurs as a result of PGE2 activation upstream in the 
RANK-L pathway. The current study demonstrates that live S. aureus strain UAMS-1 
induces significant PGE2 production in infected osteoblasts (Figure 3). However, UV-
killed S. aureus strain UAMS-1 and S. carnosus do not induce PGE2 production by 
osteoblasts. Osteoblasts infected with S. aureus nasopharyngeal isolates N1-N5 
demonstrate increased PGE2 expression initially and decreased expression subsequently 
comparable to uninfected osteoblasts. Increased and sustained levels of PGE2 production 
are only induced by live osteomyelitis clinical isolate UAMS-1, indicating the strain is 
capable of potentiating the bone damage observed in osteomyelitis. The e results along 
with the RANK-L data are consistent with our previous findings that live S. aureus strain 
UAMS-1 is more effective at eliciting immune modulator production by cultured 
osteoblasts compared to UV-killed bacteria or non-pathogenic species  (3-5, 11). 
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 The functions of PGE2 in target cells are mediated by four different G protein-
coupled receptor subtypes, EP1, EP2, EP3, and EP4 (26, 46). Among these PGE2 
receptor subtypes, EP4 is the main receptor expressed on osteoblasts and is responsible 
for mediating PGE2-induced RANK-L expression by osteoblasts (13, 46, 51).  In 
addition, PGE2 synergistically promotes the differentiation of bone marrow macrophages 
into osteoclasts induced by RANK-L and M-CSF (50, 54).  Thus, PGE2 stimulates 
osteoclastic bone resorption through the following two different pathways: the induction 
of RANK-L expression in osteoblasts, and the direct enhancement of RANK-L induced 
differentiation of osteoclast precursor cells into osteoclasts.  The mechanism of the 
synergistic effect of PGE2 on the RANK-L-induced osteoclastic differentiation of 
precursor cells has not yet been explained (21).    
 PGE2 synthesis is regulated by three metabolic steps: the release of arachidonic 
acid from the membranous phospholipids by phospholipase A2 (PLA2), the conversion of 
arachidonic acid to PGH2 by cyclooxygenase (COX), and the synthesis of PGE2 by PGE 
synthase (24, 32, 43). Both constitutive COX (COX-1) and inducible COX (COX-2) are 
expressed in mouse osteoblasts with COX-2 being markedly induced by several bone-
resorbing, inflammatory factors, including IL-1 and IL-6 in osteoblasts (30, 46).  To 
establish the role of COX-2 with respect to production of PGE2 during infection of 
osteoblasts with S. aureus, we used NS-398 to inhibit COX-2 and examined its effect on 
PGE2 expression.  When osteoblasts were treated with NS-398, PGE2 levels were 
significantly attenuated in both un-infected and S. aureus-infected osteoblasts (Figure 4).  
These results indicate that COX-2 is important in the regulation of PGE2 production 
during S. aureus infection of osteoblasts.  
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 We next examined the effects of NS-398 on the production of RANK-L.  
Although NS-398 significantly reduced the RANK-L produced by S. aureus-infected 
osteoblasts, levels of RANK-L still remained detectable and were still responsive to S. 
aureus infection (Figure 5).  These data suggest that COX-2 and PGE2 play a significant 
role in potentiating RANK-L production by S. aureus-infected osteoblasts.  
The increasing incidence in bacterial infections caused by S. aureus, and the 
emergence of antibiotic-resistant strains of this organism has made it imperative that we 
understand the mechanisms of initiation and maintenance of inflammation, s well as 
bone loss observed in sites of infection in order to develop safe and effectiv  therapies. 
Data presented here clearly outline a mechanism by which RANK-L, an essential factor 
for osteoclastogenesis, is up-regulated by S. aureus strain UAMS-1-infected osteoblasts, 
further substantiating the role that osteoblasts may have in the aberrant bone remodeling 
observed in staphylococcal osteomyelitis. In addition, this up-regulation of RANK-L 
appears to involve a COX-2 mediated PGE2-dependent pathway. Potentially, agents that 
inhibit COX-2 or block RANK-L production could ameliorate bone loss. Further studies 
are warranted to investigate the in vivo significance of RANK-L in S. aureus-induced 
osteomyelitis.  
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                                                          FIGURES 
 
 
 
Figure 1. Expression of RANK-L mRNA by osteoblasts.  Primary mouse osteoblasts 
were either uninfected (MOI 0) or were infected with S. aureus strain UAMS-1 (MOI 
25:1 or 75:1).  Following a 45-minute incubation +/- bacteria (time 0 hours), total RNA 
was extracted at various time points and subjected to Quantitative Real-time RT-PCR 
analysis for RANK-L mRNA.  All values were normalized to G3PDH and are expressed 
in fold change over baseline (0 hours, 0 MOI).  Data are expressed a  the means ± SEM 
of three separate osteoblast cultures.  *, P < 0.05 versus 75:1 MOI at 0 min; #, P < 0.05 
versus 0 MOI at time 0 min; $, P < 0.05 versus 25:1 at 4hrs.   
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Figure 2. Expression of RANK-L protein by osteoblasts.  Primary mouse osteoblasts 
were either uninfected (MOI 0) or were infected with either S. aureus strain UAMS-1 
(MOI 25:1 or 75:1), UV-killed strain UAMS-1 (MOI 25:1), S. carnosus (MOI 25:1) or 
with S. aureus nasopharyngeal isolates N1, N2, N3, N4 and N5 (MOI 25:1).  Following a 
45-minute incubation +/- bacteria and 1 hour treatment with 25 µg/ml Gentamicin 
Sulfate, whole cell extracts were taken at time 0 hours, 6 hours, and 24 hours.  RANK-L 
concentrations were determined by an ELISA and the results are displayed in pg/ml.  
Data are expressed as the means ± SEM of three separate osteoblast cultures.  *, P < 0.05 
versus 0 MOI at all time points;  #, P < 0.05 versus 75:1 MOI at 0h and 6h; $, P < 0.05 
versus 25:1 at 6h and 24h.  
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Figure 3. Expression of Prostaglandin E2 by osteoblasts.  Primary mouse osteoblasts 
were either uninfected (MOI 0) or were infected with either S. aureus strain UAMS-1 
(MOI 25:1 or 75:1), UV-killed strain UAMS-1 (MOI 25:1), S. carnosus (MOI 25:1) or 
with S. aureus nasopharyngeal isolates N1, N2, N3, N4 and N5 (MOI 25:1).  Following a 
45-minute incubation +/- bacteria and 1 hour treatment with 25µg/ml Gentamicin Sulfate, 
supernatants were collected at time 0 hours, 6 hours, and 24 hours.  Prostaglandin E2 
concentrations were determined by an EIA and are expressed in pg/ml. Data are 
expressed as the means ± SEM of three separate osteoblast cultures.  *, P < 0.05 versus 0 
MOI at 0, 6h, and 24h. 
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Figure 4.  Expression of Prostaglandin E2 and the Effects of NS-398.  Primary mouse 
osteoblasts were cultured in the presence of 0.025% DMSO or 20 µM NS-398 in DMSO, 
48 hours prior to infection.  Osteoblasts were either uninfected (MOI 0) or were infected 
with S. aureus strain UAMS-1 (MOI 25:1, or 75:1).  Following a 45-minute incubation 
+/- bacteria and 1 hour treatment with 25 µg/ml Gentamicin Sulfate, supernatants were 
collected at time 0 hours, 6 hours and 24 hours.  Prostaglandin E2 concentrations were 
determined by an EIA and are expressed in ng/ml. Data are expr ssed as the means ± 
SEM of three separate osteoblast cultures.  *, P < 0.05 versus 0 MOI treated with DMSO; 
#, P < 0.05 versus all groups treated with NS-398 at all time points. 
 21
 
Figure 5. Expression of RANK-L and the Effects of NS-398.  Primary mouse osteoblasts 
were cultured in the presence of 0.025% DMSO or 20 µM NS-398 in DMSO, 48 hours
prior to infection.  Osteoblasts were either uninfected (MOI 0) or were infected with S. 
aureus strain UAMS-1 (MOI 25:1, or 75:1).  Following a 45-minute incubation +/- 
bacteria and 1 hour treatment with 25 µg/ml Gentamicin Sulfate, whole cell extracts were 
collected at time 0 hours, 6 hours and 24 hours.  RANK-L concentrations were 
determined by an ELISA and are expressed in pg/ml. Data are exp ssed as the means ± 
SEM of three separate osteoblast cultures.  *, P < 0.05 versus 0 MOI treated with DMSO 
at 0h, 6h, and 24h; #, P < 0.05 versus all groups treated with NS-398 at all time points; $, 
P < 0.05 versus 25:1 MOI at 24h. 
 
 
 
 
 
 
CHAPTER 5: INTRODUCTION 
 
 
 Osteomyelitis is a severe infection of bone tissue that results in progressive 
inflammatory destruction of bone. It is often necessary that infected bone be debrided, 
tissues reconstructed, and long-term antibiotic therapy utilized. The gram-positive 
organism Staphylococcus aureus is the most common causative agent of osteomyelitis, 
accounting for approximately 80% of all human cases (8). These bacteria are 
characterized by their high affinity to bone, rapid induction of osteonecr sis (bone death) 
and resorption of bone matrix (20). While S. aureus is generally considered to be an 
extracellular pathogen, previous studies from our lab have demonstrated hat S. aureus 
has the ability to adhere to and persist within osteoblasts (bone-forming cells) (1, 9, 14). 
The ability of S. aureus to invade and survive within osteoblasts is critical to the 
observation that greater than 80% of all cases of chronic osteomyelitis are caused by S. 
aureus. Therefore, it is possible that the ability of bacteria to persist intracellularly offers 
the bacteria a route to evade antibiotic treatment, which could subsequently lead to 
recurrent infections.  
Biodegradable biocompatible polymer nanoparticles are effective drug delivery 
systems (35, 36). The biodegradability and biocompatibility of poly (lactic id) PLA and 
poly(lactide-co-glycolide) PLGA has been well documented (10, 11). One of the 
advantages of these systems for drug delivery is reduction in systemic complications and 
allergic reactions due to the feasibility of delivering the drug locally (6). In addition, no 
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follow-up surgical interference is required once the drug supply is depleted (21). Lastly, 
biodegradation occurs by simple hydrolysis of the ester backbone in aqueous 
environments such as body fluids and the degradation products are then metabolized to 
carbon dioxide and water. Biodegradation of these polymers offers potential use in drug 
delivery, either as drug delivery systems alone or in combination with other medical 
devices. Drug (the active agent) can be incorporated within the polymer matrix (the 
carrier), which later degrades in the body releasing the drug in a controlled way (22). 
Some controlled release devices include microspheres (5, 24), rods (28), films (19) and 
nanoparticles (18). Several techniques such as single emulsion-solvent evaporation 
technique have been developed to prepare nanoparticles loaded with a broad variety of 
drugs using PLGA (3, 12, 17, 32).  
The goal of this study was to develop PLGA based nanoparticles for the delivery 
of antibiotics such as nafcillin, an amphiphilic pencillin (13), to intracellular bacteria 
inside osteoblasts. Polyvinyl alcohol (PVA) was used as a copolymer because 
nanoparticles using this emulsifier are relatively uniform and smaller in size, and are easy 
to redisperse in aqueous medium (26). As proof of concept, PLGA nanoparticles were 
first linked to quantum dots to model the diffusion of antibiotic-nanoparticles into 
osteoblasts and subsequently loaded with nafcillin to evaluate the viability of ntracellular 
S. aureus inside infected osteoblasts.  
Quantum dots (QDs) are a new class of fluorophores excitable over a broad 
wavelength range stretching from the UV up to slightly less than their emission peak. 
They have narrow, size-tunable emission bands, and are resistant to photobleaching. 
Their biological applications in a variety of in vitro and in vivo procedur s including 
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methods of labeling cells with them have been reported (4, 16, 33). In this investigation 
In/Ga/P amine functionalized QDs were used to model the diffusion of the nanoparticles 
within the osteoblasts by adding PLGA-encapsulated InGaP/ZnS nanoparticles to 
confluent cultures of primary mouse osteoblasts. Following Prefer fixation, cultures were 
examined via confocal microscopy. Fluorescent confocal microscopy results verified that 
PLGA loaded nanoparticles tagged to quantum dots diffused inside osteobla ts and were 
located in the periphery of the nucleus (29). 
Subsequently, PLGA particles loaded with nafcillin were constructed and 
characterization and drug-loading studies were performed by UV-Visible 
spectrophotometry, dynamic light scattering and scanning electron microscopy (SEM). In 
addition, viability studies were conducted in primary osteoblasts intracellularly-infected 
with S. aureus. Following 24 and 48 h of incubation, all formulations of nanoparticles 
loaded with nafcillin either killed or significantly reduced all of the intracellular bacteria. 
Our data thereby demonstrate that effective killing of intracellular S. aureus is possible 
by treating the infected osteoblasts with nanoparticles loaded with nafcilli  (27). 
 
 
 
 
 
 
CHAPTER 6: MATERIALS AND METHODS 
 
 
PLGA Nanoparticles preparation 
Materials: 
 Poly(dl-lactide-co-glycolide) MW. 12,000-16,000, (PLGA) (50:50), poly(d -
lactide-co-glycolide) MW 20,000, (75:25) and poly(vinyl alcohol) MW 6000, (PVA) (80 
mol% hydrolyzed) were purchased from PolySciences, Inc (Warrington, PA). Nafcillin 
Sodium was obtained from Sandoz Inc (Broomfield, CO). Quantum dots (QD), T2-MP 
InGaP/ZnS Amine Macoun Red, 650nm was obtained from Evident Technologies. 
Sodium Chloride, potassium chloride, sodium phosphate, dibasic, potassium phosphate, 
monobasic  and dimethyl sulfoxide (DMSO) were purchased from VWR international 
(West Chester, PA), SpectraPor 1 dialysis tubing (MWCO 6-8 kDa) and SpectraPor 2 
dialysis tubing  (MWCO 12-14 kDa) (Spectrum Laboratories, Inc) were used. 
Collagenase (375 microgram/ml, type VII), protease (7.5 microgram/ml), Dulbecco's 
modified Eagle's medium, glycine, ascorbic acid, vitamin B12, p-amino benzoic acid, 
penicillin, streptomycin and amphotericin B were obtained from Sigma Chemical Co (St. 
louis, MO). Fetal bovine serum was purchased from Atlanta Biologicals (GA). Accugene 
Molecular Biology Grade Water (Lonza, Rockland, ME) was used for all preparations. 
All reagents were either American Chemical Society Analytical Grade Reagents or 
HPLC grade. 
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 Emulsion- solvent evaporation technique: 
 In this study PLGA nanoparticles using several copolymer molecular weights 
were prepared by the single emulsion-solvent evaporation technique (3, 35). The lactide 
content of the copolymers varied from 50, 75 to 100%. The effect of the stabilizer in the 
nanoparticle size was studied by using different amounts of polyvinyl alcohol (0, 0.5, 1, 
2, and 2.5%). Poly (vinyl alcohol) (PVA) was used as surfactant becaus nanoparticles 
using this emulsifier are relatively uniform and smaller in size, and are easy to redisperse 
in aqueous medium (26). Also, nanoparticles loaded with amine functionalized quantum 
dots composed of an In/Ga/P core surrounded by a ZnS shell and a PEGlipid coating 
functionalized with an amine linker group were prepared.  
For nanoparticles loaded with quantum dots (QD), 3 ml of QD solution in double 
distilled ionized water at a concentration of 9 x 104 nmol/ ml was prepared and added to 
the PLGA organic phase and vortexed for 3 min. PLGA organic phase w prepared by 
dissolving 300 mg PLGA in 10ml dichloromethane and acetone mixture (8:2, v/v) by 
vortexing. 20 mL of aqueous PVA solution was prepared at concentrations of 0.5, 1, 2, 
and 2.5% w/v. The oil-water (O/W) emulsion was obtained by pouring the organic phase 
into the aqueous phase, vortexing for a min and then sonicating with a probe at 90W for 
15 minutes over an ice bath. The organic solvents were allowed to evap rate while being 
stirred at atmospheric pressure. The solidified nanoparticles were collected by 
ultracentrifugation at 10000 rpm for 15 min to eliminate the big nanoparticles, and then 
washed three times with double distilled ionized water at 35,000 rpm for 30 minutes. The 
final product was dried by lyophilization. 
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For nanoparticles loaded with nafcillin, 300 mg PLGA was dissolved in 10 ml 
dichloromethane and acetone mixture (8:2, v/v) by vortexing. 100 mg of Nafcillin sodium 
was dissolved in 10 ml of the co-solvent, acetone and 18 drops of water wer  added. 
These two organic phases were mixed together by vortexing and addeto 20 ml 0.5% 
PVA solution. Then the mixture was sonicated for 15 minutes (amplitude 75) (Vibracell, 
VCX 130PB, Sonics and Materials, Inc., Newtown, CT) over an ice bath. An oil in water 
(o/w) emulsion was formed. The organic solvents were evaporated at atmospheric 
pressure for 72 hours under constant stirring (250 rpm). The precipitated n noparticles 
were collected by ultracentrifugation (20,000 rpm, 30 min). Nanoparticles were washed 3 
times with water followed by ultracentrifugation to remove excess PVA and nafcillin 
sodium. Purified nanoparticles were dried by lyophilization. Unloaded PLGA 
nanoparticles (nanoparticles without nafcillin) were also prepared by single 
emulsion/solvent evaporation method.  
Characterization of nanoparticles: 
Particle Size, Zeta potential and Morphology: 
0.1 mg of nanoparticles were suspended in 5 ml of double distilled ionized water 
and the suspension was sonicated for 5 min. The particle size and Zeta pot ntial of the 
nanoparticles were then determined by dynamic light scattering (Zeta Pals, Brookhaven 
Instruments corp., Holtsville, NY). The morphology of the nanoparticles was studied by 
scanning electron microscope (Raith 150, Raith USA, Ronkonkoma, NY) by spreading 
the particles over an aluminum holder.  
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Drug loading measurements:  
Drug loading of nanoparticles was determined by UV-Vis spectros opy (Cary 300 
Bio, Varian Australia PTY Ltd, Australia). Nafcillin-loaded nanoparticles were dissolved 
in DMSO and the absorbance was measured at 325 nm and 335nm (37). The drug 
concentration was determined by using calibration curves obtained from standard 
solutions of nafcillin in DMSO. 
Drug loading (%, w/w) =  mass of  drug in nanoparticles  x 100  
              mass of nanoparticles 
In vitro drug release: 
 The in vitro degradation studies as well as the early stages of the drug release 
profile have been studied using phosphate buffer saline (PBS, pH 7.4), as the release 
medium. In vitro drug release studies of nanoparticles were conducted in an icubator 
shaker (Lab line, Labline Instruments Inc, Melrose Park, ILL) in phosate buffer saline 
(PBS) (pH 7.4, 0.15M). The temperature of the system was maintained at 37ºC. 
SpectraPor dialysis tubing was used for the study. The dialysis tubing was first activated 
by treating with sodium bicarbonate and sodium EDTA. Fifty mg of nafcillin loaded 
nanoparticles were suspended in 5 ml phosphate buffer saline and placed in dialysis bag 
and both ends were sealed with clips. SpectraPor (MWCO 6000) dialysis tubing was used 
for PLGA 50:50 and SpectraPor (MWCO 12,000-14,000) dialysis tubing was used for 
PLGA 75:25. The bag was immersed into a glass bottle containing 100 ml of release 
media (PBS) and closed tightly. The system was kept under constant shaking at 100 rpm 
to keep the concentration of drug in the buffer uniform. One ml of the buffr solution was 
sampled periodically at predetermined intervals and was replaced with one ml of fresh 
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PBS. The drug concentration was measured using UV-Vis spectroscopy at 325 nm and 
335 nm using calibration curves obtained from standard solutions. The experiment was 
repeated with nafcillin sodium without polymer nanoparticles. Nafcillin sodium was 
dissolved in 5 ml PBS and loaded in a dialysis bag and the release of drug was 
determined. These results were compared with that of release from drug loaded PLGA 
nanoparticles in PBS solution.  
Viability study 
Normal mouse osteoblast cell culture:  
Primary osteoblasts were isolated from mouse neonatal calvariae by sequential 
digestion with collagenase and protease according to a method previously described for 
chick embryos (30, 31). The periostea were removed, the frontal bones wer  harvested 
free of the suture regions, and the bones were incubated for 10 min at 37°C in 10 ml of 
digestion medium containing collagenase (375 U/ml, type VII; Sigma Chemical 
Company, St. Louis, MO) and protease (7.5U/ml; Sigma). Cells released during an initial 
7 min digestion were discarded. Ten milliliters of fresh digeston medium was added, and 
incubation continued for another 20 min. Cells were harvested by centrifuga ion and 
rinsed three times in 25 mM HEPES- buffered Hanks’ balanced salt solution (pH 7.4; 
HBSS). The digestion step was repeated twice, and the three cell isolates were pooled in 
mouse osteoblast growth medium (OBGM) consisting of Dulbecco’s modified eagle 
medium containing 25 mM HEPES, 10% fetal bovine serum (Atlanta Biologicals, GA), 2 
g of sodium bicarbonate per liter, 75 mg of glycine/ml, 100 mg of ascorbic acid, 40 ng of 
vitamin B12/ml, 2 mg of p-aminobenzoic acid/ml, 200 ng of biotin/ml, and penicillin (100 
U/ml)-streptomycin (100 µg/ml)-amphotericin B (25 µg/ml) (pH 7.4) (30). Osteoblasts 
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were seeded on a coverslip in 24-well culture dishes (for confocal mi roscopy) or 6-well 
culture dishes (for viability studies) and incubated at 37°C in a 5% CO2 atmosphere until 
they reached confluence (2-7 days).  
Confocal microscopy analysis:   
Once the cells reached confluency, cells were washed once with Hank’s balanced 
salt solution (HBSS) and were treated with quantum dots alone or quantum dots tagged to 
nanoparticles suspended in 1X phosphate-buffered saline (PBS). Following different time 
periods of incubation, the quantum dots with and without nanoparticles were removed 
and rinsed twice with 1X PBS. Cell layers were rinsed twice ith 1X PBS and were fixed 
using prefer fixative (Anatech Ltd, MI) for 20 minutes. The fixative was then removed 
and the cells were washed twice with 1X PBS. Cells were counterstained with 4’-6-
diamidino-2-phenylindole (DAPI) for 10 minutes to visualize the nucle s, which stains 
blue with DAPI. The excess DAPI stain was then removed and cells w re washed twice 
with 1X PBS. Finally, the extent of fluorescence present in the cells was visualized using 
a FLUOVIEW FV500 confocal laser scanning biological microscope (Olympus America 
Inc., Melville, NY). 
Bacterial strain and growth conditions: 
 Staphylococcus aureus strain UAMS-1 (ATCC 49230) is a human osteomyelitis 
clinical isolate, and was grown overnight with aeration in 75 ml of Tryptic soy broth 
(TSB) at 37°C. The bacteria were harvested by centrifugation at 4300 x g for 10 minutes 
at 4°C and the cell pellet was resuspended in osteoblast growth medium (OBGM) lacking 
antibiotics. Following resuspension of bacteria in OBGM, bacterial cell density was 
determined via spectrophotometric analysis. 
 31
Invasion assay and S. aureus viability:  
PLGA (50:50) and PLGA (75:25) loaded with nafcillin were used for the study. 
Samples G1 (PLGA 50:50, unloaded), G2 (PLGA 75:25, unloaded), G1.1 (PLGA 50:50, 
loaded), G1.2 (PLGA 50:50, loaded), G2.1 (PLGA 75:25, loaded) and G2.2 (PLGA 
75:25, loaded) were used in these experiments. Nafcillin loaded particles were suspended 
in the growth medium at a concentration of 100 µg/ml. Once the osteoblasts reached 
confluency, cells were washed with OBGM lacking antibiotics and treated with 75 µl of 
the S. aureus suspension (approximately 2 x 109 colony forming units) in OBGM lacking 
antibiotics. Following a 45 min infection at 37°C, bacteria were removed and cell 
cultures were washed once with OBGM lacking antibiotics. Cells were then incubated for 
1 hour at 37°C in OBGM containing either gentamicin (25 µg /ml) (to kill remaining 
extracellular bacteria) and unloaded nanoparticles or OBGM containing gentamicin and 
nafcillin loaded nanoparticles. Following 1 hour incubation period (time 0 hour), OBGM 
containing nanoparticles were removed and the cells were eitherlysed by treating with 
0.1% triton X 100 for 5 minutes at 37°C or the cells were incubated for an additional 24-
48 hours and then lysed.  Serial dilutions of the cell lysates were plated on to tryptic soy 
agar plates (TSA) and the numbers of viable intracellular bacteri  were quantified 
following an overnight incubation of the plates at 37°C.   
Statistical analysis:  
Data are all expressed as mean ± S.E.M utilizing three indepe nt osteoblast 
cultures. The statistical significance of results was analyzed using a student t-test 
(Sigmastat, SPSS Inc.) and a p value of less than 0.05 was considered significant. 
 
 
 
 
 
 
CHAPTER 7: RESULTS 
 
 
Intracellular diffusion of quantum dots tagged to nanoparticles into osteoblasts: 
 In the present study, we tested the ability of nanoparticles loaded with nafcillin to 
cross the osteoblast cell membrane to ensure better drug delivery to intracellular bacteria. 
To provide proof of concept, we first examined the ability of nanoparticles tagged to 
quantum dots to be incorporated inside osteoblasts. Nanoparticles of poly (lactide-co-
glycolide) were prepared by single emulsion solvent evaporation technique. Three 
different copolymer compositions were used and the amount of the emulsifier, polyvinyl 
alcohol (PVA), was also varied. The particle size of nanoparticle suspensions was 
determined and results are summarized in Table 1. Primary mouse osteobla ts were then 
treated with these quantum dots tagged to PLGA nanoparticles. After incubation periods 
of 1 and 2 h followed by Prefer fixation, the cultures were examined via confocal 
microscopy to observe the extent of fluorescence present in the cells. As shown in Fig. 1, 
the tagged particles were internalized by osteoblasts and were located adjacent to the 
osteoblast nuclei.  
Characterization of nanoparticles loaded with nafcillin: 
 Nanoparticles were then loaded with nafcillin and the particle size of nanoparticle 
suspensions along with the drug loading of the dry nanoparticles was determined and 
results are summarized in Table 2. Scannin electron microscopy imaging of nanoparticles 
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shows that they are spherical in shape with a smooth surface (Fig. 2). The zeta potential 
of plain PLGA nanoparticles was measured to be -45 mV. The release of nafcillin from 
nafcillin-PBS solution loaded in a dialysis bag is shown in Figs. 3a and 3b. The release of 
nafcillin from nafcillin-PBS solution without polymer nanoparticles followed a rapid 
profile with 97% of the drug being released within the first 9 h. Figs. 4 and 5 show the 
release of nafcillin from PLGA 75:25 and PLGA 50:50 respectively. The drug release 
followed a biphasic profile with 42-47% of the drug being released within 48 h of study 
(burst release) and the entire drug released within 35-40 days.  
Viability of S. aureus inside osteoblasts exposed to nafcillin loaded nanoparticles:  
As detailed in Fig. 6, following 24 and 48 hours of incubation, all formulations of 
nanoparticles loaded with nafcillin significantly reduced the numbers of intracellular 
bacteria. G1.2 and G2.2 formulations of nanoparticles loaded with nafcillin kil ed all of 
the intracellular bacteria. Other loaded formulations of particles, G1.1 and G2.1, caused a 
significant decrease in the viability of intracellular S. aureus inside infected osteoblasts. 
For all time points, the numbers of intracellular bacteria from osteoblasts infected with S.
aureus, in the absence of any further treatment, were comparable to the numbers of 
bacteria obtained from infected osteoblasts treated with the unloaded nanoparticles 
formulations (G1 and G2).  
 
 
 
 
 
 
CHAPTER 8: DISCUSSION 
 
  
Osteomyelitis is an inflammatory disease of the bone that is chara terized by 
extensive bone destruction and its primary causative bacterium is Staphylococcus aureus. 
The organism is a capable bone pathogen, with adhesins that facilitate its binding to bone 
matrix and toxin secretion capable of stimulating bone resorption via increasing 
osteoclast activity (23, 25).  Previous studies in our lab have shown that S. aureus can be 
internalized by osteoblasts (14). Intracellular invasion provides protection from the 
humoral immune response and several classes of antibiotics. These factors, coupled with 
the fact that antibiotics cannot effectively penetrate intracellularly-infected eukaryotic 
cells could explain the recalcitrant nature of this disease despite what can be considered 
adequate surgical and antibiotic management (7). We have successfully demonstrated the 
use of nafcillin-loaded nanoparticles to target intracellular S. aureus. Nafcillin was 
chosen in these studies, since S. aureus clinical isolate UAMS-1 is sensitive to the drug, 
nafcillin is often prescribed for S. aureus infections, and nafcillin does not have the 
ability to enter eukaryotic cells in its native form.  
Poly(lactide-co-glycolide) [PLGA] particles were first tagged to quantum dots 
(In/Ga/P amine functionalized QDs) in order to model the diffusion of the nanoparticles 
across the osteoblast cell membrane. The QD was composed of an In/Ga/P core 
surrounded by a ZnS shell and a lipid coating to make it water soluble. Other bio-
molecules such as antibiotics can be potentially conjugated to the amin  linker group 
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functionalized to the lipid coat. PLGA nanoparticles were prepared by single-emulsion 
solvent evaporation technique and the lactide content of the copolymers varied from 50, 
75 to 100%. The effect of the stabilizer in the nanoparticle size was studied by using 
different amounts of polyvinyl alcohol (0, 0.5, 1, 2, and 2.5%). For all copolymer 
compositions, optimum results in terms of particle size and nafcillin loading was obtained 
when 0.5% of PVA was used to prepare the PLGA nanoparticles (data not shown) and 
was henceforth chosen as the optimum stabilizer concentration for preparation of PLGA 
particles loaded with nafcillin. An interesting phenomenon observed was the reduction in 
the particle size of nanoparticles upon loading of nafcillin compared to that of unloaded 
PLGA nanoparticles (Table 2). As observed in other studies, a hydrophobic drug such as 
nafcillin with its aromatic rings in its molecular structure, might decrease the interfacial 
tension between the aqueous phase and the organic phase, which results in an increase of 
the area to volume ratio which results in a reduction of particle siz  (38). The PLGA 
nanoparticles prepared in these studies were spherical in shape, with part cle size in the 
range of 200 nm (Fig. 2). The negative zeta potential of these particles, due the presence 
of free carboxyl groups on the polymer surface, was in agreement with previous studies 
(15). Fluorescent confocal microscopy verified that PLGA nanoparticles loaded with 
QDs diffused inside osteoblasts and were located in the periphery of the nucleus (Fig. 1) 
(29). 
We then evaluated the drug release profiles of nafcillin loaded PLGA 
nanoparticles. Firstly, the drug release profile of nafcillin soluti n in PBS across dialysis 
tubing was measured and the majority of the drug was rapidly released within the first 9 
hours (Fig. 3). This shows that the transport of drug through the dialysis membrane is not 
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a rate-limiting factor. Drug release measured from nafcillin-loaded PLGA nanoparticles 
followed a biphasic profile with an initial rapid release followed by a more controlled 
release as shown in Figs. 4 and 5. Biodegradable polymers can be arbitrarily classified 
into two groups - bulk eroding (homogeneous) and surface eroding (heterogen ous) 
polymers. In the case of surface-eroding polymers, polymer degra ation is much faster 
than water intrusion into the polymer bulk and hence, the erosion affects only the surface 
and not the inner parts of the matrix. In bulk eroding polymers, water uptake by the 
system is much faster than polymer degradation which results in the hydration of entire 
polymer and cleavage of polymer chains inside the polymer. The erosion process is 
therefore not confined to the outer surface alone. PLGA is documented to be a bulk 
eroding polymer (2, 34) as corroborated by the release profile observed her . The initial 
burst release was probably due to the drug that was present close to the surface and the 
second phase of slow release was due to simultaneous polymer degradation and drug 
diffusion. Such a release profile is important because an initial burst release may help 
control the rapid growth of the organism in osteoblasts.  
Lastly, we investigated the effects of nafcillin-loaded PLGA nanoparticles on the 
viability of intracellular S. aureus in infected osteoblasts. Our viability study data 
demonstrate that effective killing of intracellular S. aureus is possible by treating the 
infected osteoblasts with nanoparticles loaded with nafcillin. These particles released the 
drug and eliminated all of the intracellular bacteria following a  incubation period of 24-
48 h (27). 
In summary, we have provided compelling data substantiating a novel approach 
using antibiotic-loaded nanoparticles to enter inside infected osteoblasts which results in 
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killing of all intracellular bacteria. One of the potential applications of such a unique 
approach can be the development of a spray device that can be used to immediately treat 
injured patients, target extracellular and intracellular bacterial pathogens and be a topical 
application replacing systemic antibiotic therapy with the associated risk of selection for 
resistant bacteria. 
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                                                          FIGURES 
 
 
Table 1: Characterization of poly(lactide-co-glycolide) [PLGA] nanoparticles tagged to 
Quantum dots (QD) prepared by emulsion solvent evaporation technique. 
 
  
 
 
Figure 1: Confocal microscopy images of poly(lactide-co-glycolide) [PLGA] 
nanoparticles tagged to quantum dots (QD) (50:50; upper panel, 75:25; lower panel) 
inside primary mouse osteoblasts. Quantum dots fluoresce red while osteobla t nuclei 
fluoresce blue. 
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Sample     Type of      Weight of    Weight of     Weight of    Particle    Zeta              Drug 
 number     polymer      PLGA           PVA          Nafcillin      Size        Pot             Loading 
                                       (mg)             (mg)             (mg)         (nm)       (mV)          (%, w/w)                                             
 G1        PLGA 50:50     900               305               Nil            373        - 45                ----- 
 G1.1     PLGA 50:50     910               306               310           140        - 78                 10   
 G1.2     PLGA 50:50     908               305               300           168        - 77                 09 
 G1.3     PLGA 50:50     300               100               100           160        - 66                 10   
 G2        PLGA 75: 25    905               102               Nil            280        - 45                -----        
 G2.1     PLGA 75:25     905               300               305           162        - 84                 07 
 G2.2     PLGA 75:25     903               300               305           207        - 82                 11      
 G2.3     PLGA 75:25     302               101               100           180        - 73                 12 
 
 
Table 2: Characterization of poly(lactide-co-glycolide) [PLGA] unloaded and nafcillin 
loaded nanoparticles prepared by emulsion solvent evaporation technique. 
 
 
 
Figure 2: Scanning electron micrograph (SEM) of a PLGA nanoparticle 
 
Figure 3: Release of drug from nafcillin-PBS solution loaded in a dialysis bag at 
37°C. a) MWCO 6 kDa; b) MWCO 12-14 KDa. 
a) b) 
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Figure 4: Release of nafcillin from PLGA 75:25 nanoparticles in PBS at 37°C. 
 
Figure 5: Release of nafcillin from PLGA 50:50 nanoparticles in PBS at 37°C 
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Figure 6: Viability of intracellular S. aureus from osteoblasts treated with nanoparticles 
or nanoparticles loaded with nafcillin. Primary mouse osteoblasts were infected 
intracellularly with S. aureus and were subsequently treated with unloaded nanoparticles 
(G1 and G2) or nanoparticles loaded with nafcillin (G1.1, 1.2, 2.1 and 2.2) for 1 (0 hour), 
24 and 48 hours. Osteoblasts were subsequently lysed at these time intervals with a 
solution containing 0.1% triton X-100 and serial dilutions of the lysates were plated on 
tryptic soy agar (TSA). Following an overnight incubation at 37°C, the numbers of 
intracellular bacteria were enumerated. *, P < 0.05 versus S. aureus- treated osteoblasts at 
the same time point. 
 
 
 
 
 
 
CHAPTER 9: INTRODUCTION 
 
 
Artificial joints and orthopedic implants are used to repair or estore function to 
damaged and diseased tissue. Conventionally, such devices are constructed of metals 
such as titanium and cobalt-chromium which are relatively non-immunogenic, non-toxic, 
and resist corrosion when placed in contact with host tissues (34). However, the most 
significant problem encountered with such biomaterials is inadequat  osseointegration, or 
intimate apposition of bone to the implant surface (11). As a result, the functional 
lifespan of artificial prostheses is estimated at about 15 years which makes them 
unsuitable for active and younger patients (34). Implant failure can be caused by various 
factors, but tends to be the result of mechanical fatigue or loosening of the device. 
Enhancement of biomaterials is therefore necessary in order to increase the implant 
success rate and extend their functional lifespan.  
   Osseointegration is desirable for the clinical success of implants because it 
provides a functional connection between the implant and bone by strong bonding of the 
surrounding bone tissue on implant-material surfaces. Formation of a proper interface 
requires immediate and rigid immobilization of the implant as any implant motion can 
also cause release of particle debris which can initiate a deleterious inflammatory 
response (19).  At the cellular level, a proper interface formation requires osteoblast 
adhesion and subsequent functions pertinent to osteogenesis (2).  
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   Bone is an anisotropic and dynamic tissue consisting of cells (osteoblasts and 
osteoclasts), connective tissue (primarily type 1 collagen), and mi erals (hydroxyapatite).  
Osteoblasts form a bone matrix (the osteoid) that later becomes mineralized. The 
extracellular matrix (ECM) secreted by osteoblasts is approximately 90% collagen and 
10% non-collagenic proteins such as osteocalcin, osteonectin, sialoproteins, 
proteoglycans, osteopontin, and fibronectin (50). Successful communication between 
cells and the ECM is mediated by a family of cell surface receptors called integrins that 
stimulate signal transduction pathways and mediate osteoblast adhesion, spreading, cell 
differentiation and bone morphogenesis (21, 23, 37). Specifically, integrin act vation 
induces expression of osteoblast specific transcripts such as osteocalcin and type I 
collagen and is required for differentiation of osteoblast precursors (55).   
   Staphylococcus aureus is a gram-positive bacterium capable of binding to and 
colonizing tissues via a collection of cell-surface adhesins referred to as microbial surface 
components recognizing adhesive matrix molecules (MSCRAMMs). SCRAMMs 
recognizing collagen, bone sialoprotein, fibronectin, and fibrinogen mediate adherence of 
S. aureus to bone and biomaterials coated with host proteins (28). There is evidence that 
S. aureus can bind to cells (16, 48) and biomaterials (25, 26) directly. Interaction of S. 
aureus with host cells via MSCRAMMs can induce signal transduction, tyrosine kinase 
activity, and cytoskeletal rearrangement (15, 16) . UV-killed S. aureus is also able to 
attach efficiently osteoblasts (29). Although viable S. aureus cells are potent inducers of 
immune modulator expression by osteoblasts, UV-killed S. aureus does not induce 
significant expression of such molecules (4-6). In summary, UV-killed S. aureus can 
tenaciously bind biomaterials and effectively colonize bone which can initiate cell-
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signaling cascades that can potentiate osteogenesis. These are an intriguing combination 
of properties with respect to bone-implant interfaces and the current proposal addresses 
the efficacy of S. aureus as a novel osteoconductive coating for bone-associated 
biomaterials.   
   Here, we investigated the effects of coating Ti surfaces with dead bacteria on 
osteoblast functions pertinent to new bone formation. For this purpose, cell adh sion, 
proliferation as well as synthesis and mineralization of the extracellular matrix were 
examined using mouse calvarial osteoblasts, a well-characterized, cell culture model. 
Osteoblast differentiation on Ti-6Al-4V alloy coated with fibronectin (Ti-Fn) surfaces 
was compared to Ti-Fn surfaces coated with UV-killed S. aureus (Ti-Fn-SA). Fibronectin 
was chosen to pre-coat the polymer surface as it is pre-adsorbed on all biomaterials 
following insertion and is considered to be the model host protein that promotes S. aureus 
attachment to biomaterial surfaces (2, 52). Results of these studies demonstrate that 
compared to the Ti-Fn surface, osteoblast attachment and adhesion was e hanced on Ti-
Fn surfaces coated with bacteria. On both substrates, cell proliferation was sustained at 
comparable levels while markers of osteoblast differentiation such as collagen, 
osteocalcin, alkaline phosphatase and mineralized nodule formation were increased on 
Ti-Fn-SA alloys compared to Ti-Fn surfaces. A productive interaction of bone-associated 
biomaterials with osteoblasts, aided by S. aureus, thus suggests a unique role for S. 
aureus to increase apposition of bone to implant surfaces. 
 
 
 
 
CHAPTER 10: MATERIALS AND METHODS 
 
 
Normal mouse osteoblast cell culture: 
 Primary osteoblasts were isolated from mouse neonatal calvariae by sequential 
digestion with collagenase and protease according to a method previously described for 
chick embryos (43). The periostea were removed, the frontal bones wer harvested free 
of the suture regions, and the bones were incubated for 10 min at 37°C in 10 ml of 
digestion medium containing collagenase (375 U/ml, type VII; Sigma Chemical 
Company, St. Louis, MO) and protease (7.5U/ml; Sigma). Cells released during an initial 
7 min digestion were discarded. Ten milliliters of fresh digeston medium was added, and 
incubation continued for another 20 min. Cells were harvested by centrifuga ion and 
rinsed three times in 25 mM HEPES- buffered Hanks’ balanced salt solution (pH 7.4; 
HBSS). The digestion step was repeated twice, and the three cell isolates were pooled in 
mouse osteoblast growth medium (OBGM) consisting of Dulbecco’s modified eagle 
medium containing 25 mM HEPES, 10% fetal bovine serum (Atlanta Biologicals, GA), 2 
g of sodium bicarbonate per liter, 75 mg of glycine/ml, 100 mg of ascorbic acid, 40 ng of 
vitamin B12/ml, 2 mg of p-aminobenzoic acid/ml, 200 ng of biotin/ml, and penicillin (100 
U/ml)-streptomycin (100 µg/ml)-amphotericin B (25 µg/ml) (pH 7.4) (42). Osteoblasts 
were seeded in 25 cm2 flasks and incubated at 37°C in a 5% CO2 atmosphere until they 
reached confluence (6-7 days). Cells were then washed with 10 ml of HBSS, treated with 
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5 ml of trypsin (Sigma) for 5 min at 37°C. Following centrifugation, osteoblasts were 
seeded on to the biomaterial surfaces as described below.  
Biomaterial preparation:   
12- well polystyrene tissue culture dishes were coated with the titanium alloy Ti-
6Al-4V (hereby abbreviated as Ti) (Teledyne Allvac/Vasco, NC) using electron beam 
deposition (Varian 3125 electron beam evaporator). Ti-coated dishes wer  then treated 
with osteoblast growth medium (OBGM) supplemented with mouse Fibronectin (hereby 
abbreviated as Fn) (Affiland Company, Belgium) at a concentration of 2 µg/ml for 24 hr 
at 37° C. Following incubation, plates were rinsed with Hank’s balanced salt solution 
(HBSS) to remove unbound Fn. Selected plates were incubated an additional 24 hr with 
different doses of UV-killed S. aureus - 1 x 106, 107 and 108 numbers of bacteria per well. 
For all experiments, Ti-Fn coated plates with no bacteria (hereby ab reviated as Ti-Fn) 
served as controls for comparison with bacteria-coated surfaces (her by abbreviated as 
Ti-Fn-SA). Following incubation, plates were rinsed with HBSS to remove unbound 
bacteria. Osteoblasts subcultured from tissue culture flasks (a described above) were 
seeded into Ti-Fn +/- dead S. aureus-coated 12 well dishes at a density of 2 x 104 
cells/cm2 and incubated at 37°C at 5% CO2 for various time points. 
Bacterial strain, growth conditions and UV-killing:  
S. aureus strain UAMS-4 is a co-isogenic mutant of osteomyelitis-clini al isolate 
UAMS-1 (ATCC 49230) with an inactivated agr (accessory gene regulator) locus (20). 
The agr locus encodes a trans-activator of multiple S. aureus virulence-associated genes 
and is also responsible for growth-phase-dependent expression of cell surface and 
secreted virulence factors. The agr locus is inactive during exponential growth where cell 
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surface adhesins are maximally expressed (38). Entry into stati nary phase results in 
activation of agr, down-regulation of cell surface adhesins, and up-regulation of secreted 
proteins. Therefore, agr mutants retain the ability to colonize host tissue, but demonstrate 
decreased virulence (20, 38). UAMS-4 was grown overnight in 15 ml of tryptic soy broth 
(TSB) supplemented with erythromycin (5 µg/ml) (Em5) at 37°C with aeration. Ten ml 
of this overnight culture was then transferred to 1 liter of TSB-Em5 and grown for 3 hr in 
conditions as described above. Bacteria were harvested in the resulting exponential phase 
to ensure maximal expression of cell surface adhesions. Cells w re harvested by 
centrifugation at 4300 x g at 4°C for 10 min and washed in HBSS. Bacteria were killed 
by exposure to short-wave (254 nm) ultraviolet radiation for 5 min and ce trifuged at 
conditions described above. Subsequently, bacteria were suspended in OBGM to give the 
final concentration of 1 to 5 x 108 colony-forming units (CFU/ml). To verify successful 
killing, aliquots of the cell suspension were plated on tryptic soy agar (TSA) 
supplemented with erythromycin (10 µg/ml) (Em10), followed by incubation for 24 h at 
37oC. 
Osteoblast attachment: 
Attachment of osteoblasts to Ti in the presence and absence of UV-killed S. 
aureus was analyzed using phosphor-screen autoradiography (10). Before subculturing 
onto Ti-Fn +/- S. aureus surfaces, osteoblasts were incubated with methionine-free 
DMEM supplemented with 5 µCi/ml 35S-methionine.  Following 18 h incubation with the 
labeling medium, cells were removed from flasks using 0.05% trypsin/0.01% EDTA, 
washed in OBGM, and seeded into culture dishes prepared as described above. 
Osteoblasts suspended in the labeling medium were seeded onto Ti-Fn and Ti-Fn-SA 
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coated plates and cell attachment was assessed at 1 and 36 h. At the indicated time poin s, 
culture plates were rinsed 3 times with HBSS, air dried, and exposd to a phosphor 
screen for 2 hrs. Following exposure, the screen was analyzed using a Typhoon 8600 
Variable Mode Phosphor Imager and the pixel intensities, indicative of the relative 
number of attached osteoblasts, were measured using appropriate software (Molecular 
Dynamics, CA).   
Osteoblast adhesion:   
Cell adhesion was assessed by reduction of the yellow tetrazolium salt 3-(4.5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium 
(MTS) to the blue formazan product (Promega, WI) (18). Osteoblasts were incubated on 
Ti-Fn and Ti-Fn-SA surfaces for 1, 3, 7 and 10 days. At the indicated tim  points, culture 
medium was removed; the wells were washed with HBSS and replaced with OBGM 
without phenol red (Hyclone labs, UT). Twenty µl of MTS reagent was added to each 
well and incubated overnight at 37 °C in a humidified atmosphere with 5% CO2. The 
extent of osteoblast adhesion was determined by measuring the absorbance of the culture 
media at 540 nm in a plate reader.  
Osteoblast proliferation: 
Osteoblast proliferation was assessed by measuring incorporation of 3H-thymidine 
into osteoblasts (13). Briefly, osteoblasts were seeded onto Ti-Fn and Ti-Fn-SA-coated 
dishes as described earlier. Cells were incubated at 37oC in 5% CO2 in OBGM containing 
0.5 µCi/ml tritiated thymidine (methyl-3H) (Amersham, MA). At 24, 48, and 72 h, 
labeling media were removed from individual plates, and the wells were rinsed once with 
PBS to remove unincorporated tritiated thymidine. Adherent cells wre then lysed in 0.5 
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ml of a 5 mM Tris (pH 8.0), 20 mM EDTA, 0.5% Triton X-100 solution. Samples w re 
treated with NaOH (2.0 N), followed by HCl (2.0 N), and then incubated overnight at 4oC 
in 0.6 N perchloric acid. Cell lysates were centrifuged, the supernatant discarded, and the 
pellet resuspended in 100 uL of Tris-EDTA buffer. Liquid scintillation analysis was then 
used to quantify the amount of tritiated thymidine present in each s mple. Radioactivity 
levels (disintegrations/minute, dpm) serve as an indicator of cell proliferation on a 
particular substrate. 
Insoluble matrix collagen synthesis assay: 
 To determine the bone-matrix forming ability of osteoblasts, production of 
insoluble collagen was measured to assess the bone matrix- forming ability of osteoblasts 
as described (49). Osteoblasts suspended in OBGM were plated on Ti-Fn and Ti-Fn-SA-
coated surfaces and incubated at 37oC in 5% CO2 for 3, 6 and 9 days. Following 
incubation at the different time points, media was aspirated and cell layers were fixed for 
1 hour in picric acid: 37% formaldehyde containing 4.8% acetic acid (3:1). Cell layers 
were then air dried and stained for 1 hr with 0.1% Sirius red F3B in picric acid (Sigma) , 
a dye that binds to the [gly-x-y] helical structure found in all co agens without staining 
other components of the extracellular matrix (33, 51). The stained cell lay rs were 
washed with 0.01N HCl and the bound dye was released using 0.1 NaOH. The 
absorbance of the released dye was measured spectrophotometrically at 540 nm. 
Osteocalcin production:  
Osteoblasts were cultured in growth medium (OBGM) on Ti-Fn and Ti-Fn-SA-
coated dishes for 7, 14 and 21 days. Cell culture media was collected at the indicat d time 
points and osteocalcin production was measured in the culture media using a 
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commercially available osteocalcin enzyme linked immuno assay (ELISA) kit 
(Biomedical Technologies, Inc., MA) as described previously (53). The measurement 
sensitivity was 1 ng/ml. 
Measurement of alkaline phosphatase activity: 
Alkaline phosphatase activity was measured using an assay based on the 
hydrolysis of p-nitrophenyl phosphate (p-NPP) to p-nitrophenol (p-NP) (17 . Briefly, 
cells suspended in OBGM were seeded in 12-well plates coated with Ti-Fn and Ti-Fn-SA 
coated surfaces and incubated for 3, 6 and 9 days. At the indicated time po nts, cell 
culture media was decanted, cell layers washed once with HBSS and then lysed with 1% 
triton X-100. Enzyme activity in the cell lysate was spectrophotometrically measured at 
410 nm as released p-nitrophenol (p-NP) over a 5-minute period. Nmol product/min te 
was calculated assuming 1A410 = 64 nMol p-NP (36). Measurement of total protein 
content in each sample using the BCA protein assay kit (PIERCE, IL) was performed to 
allow a determination of alkaline phosphatase specific activities for osteoblasts attached 
to the different substrates. Alkaline phosphatase specific activity was expressed as 
nanomoles of product (p-nitrophenol) produced per milligram of protein.  
Osteoblast mineralization: 
 The degree of mineralization was determined using Alizarin Red S staining as 
described (1). Osteoblasts were suspended in mineralization media (DMEM 
supplemented with 10% FBS, 10 mM β-glycerophosphate (β-GP) and 50 µg/ml ascorbic 
acid), plated on Ti-Fn and Ti-Fn-SA-coated surfaces and incubated for 7, 14 and 21 days. 
Following the indicated times of culture, media was removed and the cells were fixed for 
1 hr with ice-cold 70% ethanol. Following fixation, cell layers were rinsed twice with 
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deionized water and stained with 40 mM Alizarin Red S solution (pH 4.2) for 10 minutes 
at room temperature. The dye was aspirated; cells were rinsed three times with deionized 
water and then washed with PBS for 10 min to remove nonspecific staining. After 
removal of the PBS, the cells were destained from the cell matrix by incubation in 10% 
cetyl-pyridinium chloride (Sigma) in 10 mM sodium phosphate (pH-7.0) for 15 minutes.  
Finally, the absorbance of the extracted stain was measured at 570nm with a 
spectrophotometer.  
Statistical analysis:  
Data are reported as mean ± SEM of triplicate values from a single experiment. 
All experiments were repeated three times and yielded similar results. The statistical 
significance of results was analyzed using a one way analysis of variance (ANOVA) with 
one repeated measure, followed by a Dunnett’s test for a p st hoc comparison (Sigmastat, 
SPSS Inc.). A p value of less than 0.05 was considered significant.  
 
 
 
 
CHAPTER 11: RESULTS 
 
 
Osteoblast attachment, adhesion and proliferation: 
 Ti-6Al-4V alloy was deposited on to tissue culture plastic and coated with mouse 
fibronectin alone (Ti-Fn surface) or with fibronectin followed by UV-killed S. aureus 
(Ti-Fn-SA). Osteoblasts were incubated on these Ti surfaces for dif erent time periods. 
Osteoblast attachment to Ti-Fn +/- S. aureus surfaces was measured by phosphor-screen 
autoradiography following 1 and 36 hours of incubation. Results from these studies 
(Fig.1) demonstrate that using dead S. aureus enhances osteoblast attachment in a dose 
dependent manner to thin films of titanium alloy, following 1 and 36 hours f incubation. 
The magnitude of attachment, as estimated by the average pixel intensity, is dependent on 
the numbers of bacteria added. When pixel intensity was quantitated by the image 
phosphor, a significant increase in attachment was noted in osteoblasts cultured in the 
presence of the 107 and 108 doses of bacteria, following 36 hours of incubation (Fig.2). 
Especially in the field of biomaterials, attachment refers to an initial 
physicochemical interaction between two surfaces mediated by ionic and van der Walls 
forces while adhesion is a more complex cellular process that involves activation of 
transcription factors, altered gene expression, and formation of focal adhesion points (2). 
Therefore, we tested if increased cell attachment in the presenc  of dead bacteria also 
resulted in corresponding increase in cell adhesion. Osteoblast adhesion on both surfaces 
was indirectly estimated by measuring the absorbance of the end product of MTS dye 
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degradation, formazan. Figure 3 shows a dose-dependent as well as kinetic increase in the 
number of osteoblasts that adhere on to Ti-Fn surfaces coated with dead S. aureus 
compared to those incubated on Ti-Fn surfaces. There is a significant increase in 
osteoblast adhesion in the presence of highest dose of bacteria following 1, 3 and 10 days 
of incubation.  
The proliferation of osteoblasts on Ti-Fn and Ti-Fn-SA surfaces was measured by 
liquid scintillation analysis following 24, 48 and 72 hours of incubation. The relativ  cell 
proliferation rate was determined by measuring the amount of 3H-thymidine 
incorporated. Data are reported as the number of disintegrations per minutes (dpm) per 
well. There were no significant differences in the proliferation rate of osteoblasts on Ti-
Fn surfaces compared to Ti-Fn surfaces coated with different numbers of dead S. aureus 
bacteria at any time point studied (Fig.4).  
Extracellular matrix synthesis and mineralization: 
 Primary mouse osteoblasts undergo an ordered sequence of differentiation which 
results in the formation of a mineralized extracellular matrix that consists of type I 
collagen, alkaline phosphatase and specialized noncollagenous proteins (50). Presence of 
a collagen matrix is required for mineralization to occur as the bone cells mineralize 
collagen by surrounding it with the hard mineral component, hydroxyapatite (HAP) 
which consists of calcium phosphate primarily (39). Osteocalcin is the second most 
abundant protein in bone after collagen and binds to both collagen and HAP. Moreover, it 
is believed to assist in the deposition of HAP onto collagen and therefor  renders the 
matrix competent for mineralization to occur. Therefore, synthesis of the total insoluble 
collagen as well as osteocalcin production was determined as an index of extracellular 
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matrix synthesis on both Ti-Fn and Ti-Fn-SA surfaces. As shown in Figure 5, the kinetics 
of total collagen synthesis, as measured by staining with a dye specific for collagen, 
Sirius red F3B, is similar when osteoblasts were cultured for time periods of 3 and 6 
days. After 9 days of incubation, however, collagen production was markedly increased 
in the presence of 107 and 108 doses of bacteria.   
The synthesis of osteocalcin protein was measured by osteoblasts on Ti-Fn and 
Ti-Fn-SA surfaces following 7, 14 and 21 days of incubation. As shown in Table 1, there 
is an at least 25-fold increase in the amount of osteocalcin produced from osteoblasts 
grown on Ti-Fn coated with the highest dose of S. aureus versus osteoblasts grown on Ti-
Fn coated dishes. Osteocalcin secretion from osteoblasts incubated on Ti-Fn alone and 
Ti-Fn surface with 106 or 107 bacteria remained below the detection limits of the assay. 
Having verified increased deposition of extracellular matrix by osteoblasts 
cultured on Ti-Fn-SA, the ability of dead bacteria to induce successful mineralization 
activity from the osteoblasts was examined. Alkaline phosphatase (ALP) is an enzyme 
that is involved in the bone mineralization process and hydrolyzes organic phosphates to 
release inorganic phosphate which is incorporated at the site of mineralization (3). 
Therefore, ALP activity was measured as an index of mineralization activity in 
osteoblasts on Ti-Fn and Ti-Fn-SA surfaces following 3, 6 and 9 days of incubation. As 
shown in Figure 6, ALP activity of osteoblasts added on both Ti-Fn and Ti-Fn-SA-coated 
dishes increased in a time-dependent manner. However, significantly greater enzyme 
activity was observed in osteoblasts incubated on the Ti-Fn surface coat d with 107 
numbers of bacteria at day 6 compared with the Ti-Fn surface.  
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When osteoblast cultures are maintained in mineralizing conditions (mouse 
osteoblast growth medium supplemented with β-glycerophosphate), calcium and 
phosphate are incorporated into the cell layers to form the mineral component (HAP). 
Alizarin red-S stains the calcium incorporated in the matrix and we can indirectly 
estimate the extent of mineralization activity by measuring the amount of calcium 
extracted from the matrix. As shown in Figure 7, there is a dose- ependent increase in 
mineralization activity in osteoblasts grown on Ti-Fn-SA-coated surfaces compared to 
Ti-Fn group following 7, 14 and 21 days of incubation in the culture media.  At all time 
periods, the highest dose of bacteria induces a significant increase in mineralization from 
osteoblasts grown on Ti-Fn-SA surface.  
 
 
 
 
 
 
CHAPTER 12: DISCUSSION 
 
 
Titanium alloys, such as Ti-6Al-4V, are the most common orthopedic implant 
materials because they offer excellent mechanical properties such as resistance to wear 
and corrosion (34). However, a major disadvantage of titanium alloys as a biomaterial is 
that they are relatively inert biologically and do not facilitate or mediate osseointegration 
which is intimate apposition of bone to the implant surface (11). Osseointegration is 
desirable because it represents formation of an appropriate interface and provides a 
functional connection between the implant and bone. A number of techniques hav  been 
employed to enhance such biomaterials, including alteration of surface oughness, 
wettability, porosity, and hydrophobicity in an attempt to enhance osseointegration and 
mediate proper interface formation (2, 34, 54). Recently, techniques have focused on 
coating implants with biological materials such as cell surface re eptors and extracellular 
matrix (ECM) components (e.g., collagen, fibronectin, and vitronectin) (9, 12, 32, 34, 35, 
41). Some of these techniques have enhanced binding of osteoblasts to implant surfaces, 
but have failed to enhance cellular functions and formation of a proper interface between 
implant and bone. Therefore, any implant surface that would promote osseointegration 
would need to facilitate osteoblast adhesion as well as proliferation nd demonstrate 
production of a mineralized extracellular matrix (ECM). 
Staphylococcus aureus is a gram-positive bacterium capable of binding to host 
cells (16, 48) and biomaterials (25, 26) directly. A collection of cell-surface adhesins 
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referred to as microbial surface components recognizing adhesive matrix olecules 
(MSCRAMMs) (28, 29) are responsible for localization of S. aureus both to bone tissue 
as well as biomaterials coated with host proteins and include adhesins such as fibronectin 
binding proteins (FnBPs), fibrinogen binding proteins, collagen-binding adhesin and 
bone sialoprotein-binding adhesin (28). MSCRAMM-mediated interaction of S. aureus 
with ECM or with osteoblasts, via integrin receptors on their surface, can induce tyrosine 
kinase activity, cytoskeletal rearrangement and signal transduction (15, 16).  
Previous studies from our lab have demonstrated that UV-killed S. aureus retain 
the ability to attach efficiently to osteoblasts but, in contrast to live bacteria, do not 
induce the expression of immune modulators such as interleukin (IL)-6, IL12 and 
monocyte chemoattractant protein (MCP-1) (4-6, 29). Therefore, as S. aureus can 
tenaciously bind biomaterials, effectively colonize bone, and stimulate signal 
transduction in host cells, we examined the efficacy of UV-killed S. aureus as an 
osteoconductive coating for titanium alloy in the current study. For all experiments, the 
ability of dead S. aureus to enhance osteoblast adhesion, proliferation and matrix 
synthesis was compared to fibronectin (Fn)-coated Ti surfaces (Ti-Fn). Fn is a component 
of plasma that coats virtually any device implanted within the body and more 
importantly, osteoblasts have been demonstrated to bind Fn preferentially when 
compared to other serum proteins (2, 52).  
Osteoblast attachment and adhesion to the implant interface is a cruci l pre-
requisite for successful osseointegration of the implant (31, 40). Our res lts show that 
osteoblasts effectively attach to Ti-Fn surfaces, both coated and uncoated, within 1 h in 
vitro. However, osteoblasts attach significantly more on Ti surfaces coated with dead 
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bacteria especially after 36 h of incubation (Fig. 1,2). Osteoblast adhesion, in contrast to 
osteoblast attachment, involves activation of transcription factors and formation of focal 
adhesion points which involves the cell membrane as well as proteins associated with the 
cytoskeleton (vinculin, talin) and ECM (fibronectin, type I collagen) (2). As indicated in 
Fig. 3, we have demonstrated that osteoblasts adhere better on Ti-Fn-SA surfaces 
compared to Ti-Fn surfaces alone and sustain increased adherence up to 10 days in 
culture. This increase in osteoblast attachment and adherence can be explained by 
enhanced hydrophilicity of the Ti-Fn surface coated with S. aureus as it has been 
established that surface hydrophilicity of a biomaterial surface greatly facilitates cell 
adhesion (2, 24). Metals, such as Ti alloy, have an oxide layer that is spontaneously 
deposited on all their surfaces and are therefore hydrophilic due to pr sence of hydroxyl 
groups present on the oxide layer (56). However, it is possible that the surface 
hydrophilicity is compromised by coating with fibronectin as would be the case in both 
Ti-Fn as well as Ti-Fn-SA substrates. However, coating the Ti-Fn alloy with bacteria 
renders the surface more hydrophilic because bacterial surfaces in aqueous solutions are 
always ionized (27). Moreover, the cell wall of S. aureus is slightly more negatively 
charged because of the presence of teichoic acids in their cell walls (22). As a result, Ti-
Fn-SA surfaces by being considerably more hydrophilic than Ti-Fn alo e substrate 
facilitate enhanced binding of osteoblasts.  
The strength of the ECM and osteoblast interactions in the presence and absence 
of dead S. aureus can also be a contributing factor for observed differences in cell 
adhesion on both substrates. Successful formation of bone requires continued dialogue 
between osteoblasts and components of the extracellular matrix (ECM), such as 
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fibronectin, type I collagen etc. Such communication between cells and the ECM is 
mediated by a family of cell surface receptors called integrins (21, 23).  It is known that 
the affinity of Fn binding to the α5β1- integrin receptor, present on the osteoblast surface, 
is much lower with a Kd =  8 x 10
-7 M compared to binding of S. aureus to fibronectin. 
Through its fibronectin-binding receptor (FnBP), there is an irreversible interaction with 
a dissociation constant of Kd = 1.8 x 10
-9 M (16). Also, in addition to FnBP, other 
MSCRAMMs present on the S. aureus surface may subsequently interact with other 
ligands of the extracellular matrix as the matrix production ensu s, further ‘cementing’ 
the osteoblasts in a cohort of multivalent ECM-cell interactions as outlined in Figure 8. 
Therefore, single process interaction of fibronectin (Fn) with in egrin on the osteoblast 
surface is weaker in strength than the array of processes possible between osteoblasts and 
ECM are potentiated by the surface receptors of the interlying bacteria. 
The developmental phase of an osteoblast involves three stages- proliferati n, 
extracellular matrix synthesis and mineralization. Therefore, a temporal sequence of 
events in osteoblast differentiation is characterized by a) active proliferation of 
osteoblasts, which is accompanied by the onset of expression of the enzyme alkaline 
phosphatase b) synthesis of high levels of several collagens (type I primarily) and other 
non collagenous proteins such as osteocalcin and osteopontin, and c) deposition of the 
mineral component, hydroxyapatite (CaPO4) in the extracellular matrix (50). We 
measured rates of proliferation of osteoblasts cultured on both Ti-Fn+/- S. aureus by 
liquid scintillation analysis. In spite of increase in cell attachment and adhesion on Ti-Fn-
SA surfaces compared to Ti-Fn alone, osteoblast proliferation occurred equally well on 
both substrates, revealing no significant differences at all times of incubation. One 
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possible explanation is that osteoblasts on Ti-Fn-SA surface, which demonstrate increase 
in all indices of bone formation (Figs. 5-7, table 1), may auto-regulate their proliferation 
rates to prevent aberrant bone deposition which is a likely scenario if there is increased 
cell proliferation. Also, Stein et al have discussed the existence of a restriction point in 
the developmental sequence of an osteoblast where a decrease in osteoblast proliferation 
is coupled with the subsequent induction of genes associated with matrix  uration and 
mineralization (50). Therefore, proliferation of osteoblasts grown on Ti-Fn-SA may be 
down-regulated following the onset of a more differentiated phenotype on the alloy 
surface (Figs. 5-7).  
We next examined the synthesis of collagen and osteocalcin which are t e key 
proteinaceous constituents of the extracellular matrix synthesized by osteoblasts. In this 
study, osteoblasts grown on Ti-Fn surfaces coated with dead S. ureus were found to 
express insoluble collagen at similar levels when compared to the uncoated levels up to 6 
days in culture, followed by a significant increase at later time points (Fig. 5). 
Osteocalcin production is also significantly upregulated on bacteri-coated alloy 
compared to Ti-Fn surface up to 3 weeks of culture (Table 1). These results suggest that 
osteoblasts cultured on dead S. aureus-coated titanium alloy demonstrate a more 
differentiated phenotype compared to their counterparts grown on Ti-Fn alone. Given that 
cell adhesion, a necessary pre-requisite for subsequent cell functions on biomaterials was 
enhanced in the presence of the bacteria, it is corroborative that synthesis of an 
extracellular matrix on bone-biomaterial interface is increased on the Ti-Fn-SA surface.  
It is well documented that osteoblast differentiation and responses during 
osseointegration are affected by implant surface topography and that increasing surface 
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roughness of implants is greatly beneficial to their biological performance as osteoblast 
differentiation is enhanced on rougher biomaterial surfaces (7, 30, 44-46). Compared to 
smoother surfaces, osteoblast proliferation on rough surfaces is impaired and phenotypes 
of cells cultured on rough surfaces shows attributes of more differentiated osteoblasts, 
such as increased osteocalcin, ALP production and mineralization activity (8, 44-46). 
These findings suggest that coating the Ti surfaces with dead bacteria could render the 
surface ‘rougher’ compared to Ti alloy alone which can explain the enhanced 
differentiation of osteoblasts on bacterial-coated surfaces versus uncoated surfaces. 
Another aspect of osteoblast differentiation is the mineralization of bone matrix 
which occurs by deposition of apatite (CaPO4) component along the collagen framework. 
Alkaline phosphatase (ALP), an enzyme characteristic of the bone pheotyp , is essential 
for matrix mineralization as it cleaves -glycerophosphate to release inorganic phosphate 
that comprises the phosphate phase of the apatite component. Non-collagen us proteins 
such as osteocalcin also support the deposition of the mineral phase.  Our findings 
demonstrate that the difference in ALP activity between Ti-Fn-SA and Ti-Fn alloy was 
maximal on day 6 and is insignificant at later time points (Fig. 6). These results are 
consistent with earlier findings where increased osteocalcin together with enhanced cell 
layer alkaline phosphatase activity have also been demonstrated on oste bla ts cultured 
on Ti surfaces with high surface energy (56), as is the case with Ti-Fn-SA alloy. As 
shown in Fig. 7, osteoblasts also showed a dose-dependent and kinetic incr ase of apatite 
deposition on surfaces coated with dead bacteria as early as day 7.Bellows et al have 
demonstrated that initiation and progression of mineralization are separat  phenomena 
and that alkaline phosphatase is critical for the former but the progression of matrix 
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mineralization is ALP-independent (3). Given the sustained mineralization activity 
demonstrated by osteoblasts on both surfaces at day 14 and 21, and the especially 
enhanced mineral deposition in the presence of dead bacteria, there must be other ALP-
independent phenomena that facilitate mineral deposition on the Ti-Fn-SA surface. One 
possible explanation is that the presence of both hydroxyl groups and an over ll negative 
charge on S. aureus cell walls facilitate the deposition of calcium and phosphate ions on 
Ti-Fn-SA surfaces. 
It is possible that the above changes in gene expression, following the interaction 
of the osteoblasts with the extracellular matrix components on the Ti-Fn-SA implant 
surface, occur as a result of differences in integrin-mediated cell adhesion and shape, 
which in turn can influence regulation of downstream signaling cascades as demonstrated 
in other studies (47). One potential downstream target molecule could be Runx2/ Cbfa1 
(Core binding factor α1), a DNA-binding transcription factor that is a critical for 
regulation of osteoblast differentiation and for the development of a mineralized 
phenotype. It can positively upregulate genes responsible for matrix synthesis (type I 
collagen, osteocalcin, osteopontin) by binding to the promoter of major osteoblast genes 
(14, 55).  
In conclusion, Ti-Fn alloy coated with dead S. aureus has been shown here to 
promote osteoblast adhesion, sustain cell proliferation and enhance the expression of a 
mineralized extracellular matrix. Collectively, these findings support our hypothesis that 
inactivated S. aureus enhances osseointegration on implant surfaces. Thus, further 
investigations are warranted to determine the biocompatibility and osseointegration of Ti-
Fn-SA alloy in animal models.   
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                                                           FIGURES 
 
1 HOUR                     36 HOURS            LAY OUT OF PLATE 
 
Figure 1. Osteoblast attachment to Ti-Fn and Ti-Fn-S. aureus-coated culture dishes at 1 
and 36 hours of incubation. Cells were cultured in standard osteoblast growth medium 
supplemented with 5 µCi/ml 35S-methionine.  The emission density, indicative of relative 
number of osteoblasts attaching to each substrate, was detected using phosphor-screen 
autoradiography. The data are representative of three separate experiments performed in 
triplicate. 
No S. aureus
106 S. aureus
107 S. aureus
108 S. aureus
}
}
}
}
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Figure 2. Average pixel intensity, an index of osteoblast attachment, as measured from 
Ti-Fn and Ti-Fn-S. aureus-coated culture dishes following 1 and 36 hours of incubation. 
Pixel intensity was calculated using the appropriate image phosphor oftware. Results are 
expressed as means ± SEM. The data are representative of three separate experiments 
performed in triplicate. * p < 0.05 compared to Ti-Fn at 36 hr. 
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Figure 3. Osteoblast adhesion to Ti-Fn and Ti-Fn-S. aureus-coated culture dishes at 1 
and 36 hours of incubation. Cells were treated with MTS dye and formati n of formazan 
product, proportional to the number of adherent cells, was spectrophotometrically 
measured at 540 nm. Results are expressed as means ± SEM. The data are representative 
of three separate experiments performed in triplicate.  * p < 0.05 compared to Ti-Fn at all 
time points. 
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Figure 4. Osteoblast proliferation rate as measured from Ti-Fn and Ti-Fn-S. aureus- 
coated culture dishes following 24, 48 and 72 hours of incubation. Cells were cultured in 
standard osteoblast growth medium supplemented with 0.5 µCi/ml tritiated thymidine 
(3H). Disintegrations per minute were determined by measuring 3H incorporation. Results 
are expressed as means ± SEM. The data are representative of three separate experiments 
performed in triplicate.   
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Figure 5. Insoluble collagen matrix synthesis activity by osteoblasts on Ti-Fn and Ti-Fn-
S. aureus-coated culture dishes following 3, 6 and 9 days of incubation.. Cells were
cultured and stained with Sirius red F3B to quantify total collagen synthesis. After elution 
with NaOH, total absorbance of the released dye was measured pectrophotometrically at 
540 nm. Results are expressed as means ± SEM. The data are repres ntative of three 
separate experiments performed in triplicate. * p < 0.05 compared to Ti-Fn at day 9. 
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Amount of osteocalcin secreted 
(ng/ml) 
No S. 
aureus 
106 / well 107 / 
well 
108 / well  
7 days < 1ng/ml < 1ng/ml < 1ng/ml > 25 ng/ ml 
(*) 
14 days < 1ng/ml < 1ng/ml < 1ng/ml > 25 ng/ ml 
(*) 
21 days < 1ng/ml < 1ng/ml < 1ng/ml > 25 ng/ ml 
(*) 
 
Table 1. Osteocalcin synthesis from osteoblasts on Ti-Fn and Ti-Fn-S. aureus-coated 
culture dishes following 7, 14 and 21 days of incubation. Concentration of osteocalcin in 
the cell culture supernatents was measured by ELISA. The data are representative of 
three separate experiments performed in triplicate. * p < 0.05 compared to Ti-Fn at the 
respective time points. 
 
 
Figure 6. Alkaline phosphatase specific activity, on Ti-Fn and Ti-Fn-S. aureus-coated 
culture dishes following 3, 6 and 9 days of incubation. Cells were cultured and enzyme 
activity was measured by conversion of a p-Nitrophenol Phosphate (p-NPP) substrate to 
p-Nitrophenol (p-NP). Specific activites are expressed as nmol of p-Nitrophenol 
produced per minute per millgram of protein. Results are expressed a means ± SEM. 
The data are representative of three separate experiments performed in triplicate. * p < 
0.05 compared to Ti-Fn at day 6. 
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Figure 7. Osteoblast mineralization on Ti-Fn and Ti-Fn-S. aureus-coated culture dishes 
following 7, 14 and 21 days of incubation. Cells were cultured and stained with alizarin 
Red S to quantify the extent of mineralization. Alizarin red S was then eluted and 
measured spectrophotemetrically at 570 nm. Results are expressed as m ans ± SEM. The 
data are representative of three separate experiments perform d in triplicate. * p < 0.05 
compared to Ti-Fn at the respective time points. 
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Figure 8. Schematic to describe binding interaction of osteoblasts on implant surfaces. a) 
Ti-Fn implant; b) Ti-Fn-SA implant, Titanium, Ti; Fibronectin, Fn; Osteoblast, Osb; 
Extracellular matrix, ECM. 
 
 
 
 
 
 
CHAPTER 13: INTRODUCTION 
 
  
Artificial joints and orthopedic implants are used to repair or estore function to 
damaged and diseased tissue. Following insertion, the host response to implants involves 
a series of events, both at a cellular and molecular level, which ideally should result in 
osseointegration. Depending on the surface properties and composition of the 
biomaterial, osseointegration has been defined either as direct bone apposition on the 
implant surface or indirectly, with a fibrous layer at the bone-implant surface (1, 33). The 
clinical success of such devices is dependent upon them fulfilling several criteria such as 
a) biocompatibility, b) intimate deposition of bone onto the implant surface, nd c) 
dissipation of forces resulting from the load by the implant on to surrounding bone (32). 
In the long term, the newly formed bone may persist and undergo remodeling depending 
on the mechanical stresses it needs to transfer during load-bearing. 
Of the various implant materials, titanium (Ti) and cobalt-chromium (Co-Cr) 
alloys as well as bioactive ceramics such as calcium phosphate, principally 
hydroxyapatite, and bioglass are most commonly used (32). However, Titanium lloys 
such as Ti-6Al-4V are the preferred material of choice for orthopedic applications as it 
offers excellent biocompatibility due to  the interaction of its spontaneously formed oxide 
layer with biological fluids, resistance to corrosion and excellent mechanical properties 
(31, 32). However, a major disadvantage of titanium alloys as a biomaterial is that they 
are relatively bio-inert and do not facilitate or mediate sufficient bone growth or contact 
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around the implant.  Considerable strategies have therefore been developed to generate 
either osteoconductive, providing a template for new bone growth, or osteoinductive, 
inducing bone formation, Ti-based biomaterials. Some of these strategies include 
modulating the implant surface by applying coatings of hydroxyapatite (HAP), bone 
sialoprotein (BSP), cell adhesion peptides; Arg-Gly-Asp (RGD) and osteotropic growth 
factors such as bone morphogenetic proteins: BMPs and transforming growth factor-beta; 
TGF-β (12, 14, 17, 34). Several studies have also examined the ability of surface textures 
(plasma spray coating, acid etching and sand blasting) to stimulate bone formation in 
vivo (30, 41, 44, 45). However, there are still long-term complications and limitations 
associated with these methods such as high temperatures needed for coating in case of 
HAP which in turn alters both mineral as well as metal structure and variable thickness of 
deposited coatings and their subsequent dissolution from the substrates (5, 6, 17, 41). In 
addition, the short half-life of osteoinductive growth factors along with their high 
concentrations locally can cause ectopic bone formation which is of concern in their 
applications. Lastly, not all of the above surface treatments involve biologically-specific 
receptor-mediated mechanisms. 
Bone is an anisotropic and dynamic tissue consisting of cells (osteoblasts and 
osteoclasts), connective tissue (primarily type 1 collagen), and mi erals (hydroxyapatite).  
Osteoblasts form a bone matrix (the osteoid) that later becomes mineralized. The 
extracellular matrix (ECM) secreted by osteoblasts is approximately 90% collagen and 
10% non-collagenic proteins such as osteocalcin, osteonectin, sialoproteins, 
proteoglycans, osteopontin, and fibronectin (39). On a macroscopic scale, bone can b  
classified as dense areas with cavities called compact/cortical bone and areas with many 
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cavities called spongy/trabecular/cancellous bone. In long bones, such a  the femur and 
tibia, the bulbous ends are comprised primarily of spongy bone surrounded by a thin 
layer of cortical bone. The central shaft region, the diaphysis, consists mostly of cortical 
bone around the bone marrow cavity. Microscopically, bone can exist as 
primary/immature/woven bone and secondary/mature/lamellar bone. Woven bone is 
temporarily formed either during embryonic development or during bone repair processes 
and is characterized by random deposition of collagen fibers. It is subsequently replaced 
by the lamellar bone which consists of organized deposition of collagen. Bone formation 
can also be divided into two categories: endochondral ossification, in wh ch bone 
formation takes place by replacing pre-existing cartilage and intramembranous 
ossification, in which bone formation occurs by direct matrix deposition and subsequent 
mineralization by osteoblasts (35). 
Staphylococcus aureus is a gram-positive bacterium capable of binding to and 
colonizing tissues via a collection of cell-surface adhesins referred to as microbial surface 
components recognizing adhesive matrix molecules (MSCRAMMs). SCRAMMs 
recognizing collagen, bone sialoprotein, fibronectin, and fibrinogen mediate adherence of 
S. aureus to bone and biomaterials coated with host proteins (25). There is evidence that 
S. aureus can bind to cells (16, 37) and biomaterials (23, 24) directly. Interaction of S. 
aureus with host cells via MSCRAMMs can induce signal transduction, tyrosine kinase 
activity, and cytoskeletal rearrangement (15, 16) . UV-killed S. aureus is also able to 
attach efficiently osteoblasts (26). Although viable S. aureus cells are potent inducers of 
immune modulator expression by osteoblasts, UV-killed S. aureus does not induce 
significant expression of such molecules (7-9). In summary, UV-killed S. aureus can 
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tenaciously bind biomaterials and effectively colonize bone which can initiate cell-
signaling cascades that can potentiate osteogenesis. These are an intriguing combination 
of properties with respect to bone-implant interfaces and the current work addresses the 
efficacy of S. aureus as a novel osteoconductive coating for bone-associated biomaterials. 
In the previous chapter, we investigated the in vitro effect of oating Ti surfaces 
with dead bacteria on osteoblast functions pertinent to new bone formati n. Osteoblast 
differentiation on Ti-6Al-4V alloy coated with fibronectin (Ti-Fn) surfaces was compared 
to Ti-Fn surfaces coated with UV-killed S. aureus (Ti-Fn-SA). Fibronectin was chosen to 
pre-coat the polymer surface as it is pre-adsorbed on all biomaterials following insertion 
and is considered to be the model host protein that promotes S. aureus attachment to 
biomaterial surfaces (3, 43). Results of those studies, discussed in the preceeding chapter, 
demonstrate that compared to the Ti-Fn surface, osteoblast attachment and adhesion was 
enhanced on Ti-Fn surface coated with bacteria. On both substrates, cell prolif ration was 
sustained at comparable levels while markers of osteoblast differentiation such as 
collagen, osteocalcin, alkaline phosphatase and mineralized nodule formation were 
increased on Ti-Fn-SA alloy compared to control surfaces. The present study was 
designed to evaluate the tissue response to Ti-Fn-SA implanted in rat femurs. The pilot 
data, from histological and electron microscopy studies, showed no significant 
inflammatory response and also demonstrated that the osteoconductivites of both 
surfaces, Ti-Fn and Ti-Fn-SA, are comparable at 8 weeks post-operati n. Further studies 
to evaluate the mechanical strength of the implants are warranted.    
 
 
 
 
CHAPTER 14: MATERIALS AND METHODS 
  
Animals:  
 Sprague-Dawley male rats (Charles River Laboratories, MA) weighing 
approximately 450 g were used in this study. All the animals were housed in a 
temperature-controlled room and were given water and food ad libitum throughout the 
study. The IACUC of University of North Carolina at Charlotte approved the 
experimental protocol used in this study.   
Implant material preparation:   
Orthopedic implant grade Ti-6Al-4V wires were a generous gift from Perryman 
Company, PA. Ti wires were then trimmed to 15 mm in length and 1.64 mm in diameter 
and sterilized with 100% alcohol and stored until use. Wires were then treated with 
osteoblast growth medium (OBGM) supplemented with rat fibronectin (hereby 
abbreviated as Fn) (Affiland Company, Belgium) at a concentration of 2 µg/ml for 24 hr 
at 37° C. Following incubation, wires were rinsed with Hank’s balanced salt solution 
(HBSS) to remove unbound Fn. Ti wires were incubated an additional 24 hrwith 108 
UV-killed S. aureus. For all experiments, Ti-Fn coated wires with no bacteria (hereby 
abbreviated as Ti-Fn) served as controls for comparison with bacteria- oated surfaces 
(hereby abbreviated as Ti-Fn-SA). Following incubation, wires were rins d with HBSS to 
remove unbound bacteria and implanted inside rat femurs during the surgical procedure.  
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Bacterial strain, growth conditions and UV-killing:  
S. aureus strain UAMS-4 is a co-isogenic mutant of osteomyelitis-clini al isolate 
UAMS-1 (ATCC 49230) with an inactivated agr (accessory gene regulator) locus (18). 
The agr locus encodes a trans-activator of multiple S. aureus virulence-associated genes 
and is also responsible for growth-phase-dependent expression of cell surface and 
secreted virulence factors. The agr locus is inactive during exponential growth where cell 
surface adhesins are maximally expressed (36). Entry into stati nary phase results in 
activation of agr, down-regulation of cell surface adhesins, and up-regulation of secreted 
proteins. Therefore, agr mutants retain the ability to colonize host tissue, but demonstrate 
decreased virulence (18, 36). UAMS-4 was grown overnight in 15 ml of tryptic soy broth 
(TSB) supplemented with erythromycin (5 µg/ml) (Em5) at 37°C with aeration. Ten ml 
of this overnight culture was then transferred to 1 liter of TSB-Em5 and grown for 3 hr in 
conditions as described above. Bacteria were harvested in the resulting exponential phase 
to ensure maximal expression of cell surface adhesions. Cells w re harvested by 
centrifugation at 4300 x g at 4°C for 10 min and washed in HBSS. Bacteria were killed 
by exposure to short-wave (254 nm) ultraviolet radiation for 5 min and ce trifuged at 
conditions described above. Subsequently, bacteria were suspended in OBGM to give the 
final concentration of 1 to 5 x 108 colony-forming units (CFU/ml). To verify successful 
killing, aliquots of the cell suspension were plated on tryptic soy agar (TSA) 
supplemented with erythromycin (10 µg/ml) (Em10), followed by incubation for 24 h at 
37oC. 
 
 77
Surgical procedure:   
Thirty minutes prior to surgery, rats were given 0.05 mg/kg buprenorphine HCL 
(Reckitt and Colmant Pharmaceuticals Inc., VA) and 5 mg/kg Carprofen as analgesics. 
Animals were then anesthetized by utilizing isofluorane and the skin of the lef  f mur was 
shaved and cleaned with 70% ethanol. Under aseptic conditions, the skin, muscle fascia 
and periosteum were retracted using an 18-gauge needle to gain access to the distal 
epiphysis. A Dremel drill with a 1.5 mm autoclaved bit was used to penetrate the cortical 
bone of the patellar groove to gain access to the femoral medullary canal. The canal was 
further reamed with a 16-gauge needle and the implants (Ti-Fn or Ti-Fn-SA) were press-
fitted into the shaft of the femur. Some holes were left empty as controls which would 
constitute the ‘reaming’ only experimental group. One femur was operated per animal 
and the contralateral femur was utilized as the unoperated control. After insertion of the 
implant, the skin was sutured using autoclips. Postoperative analgesia wa  ensured by 
subcutaneous injection of buprenorphine HCL (Reckitt and Colmant Parmaceuticals, Inc., 
VA) (0.05 mg/kg) every 12 h for 24 h. If the animals were weight-bearing on the 
operated leg and were ingesting rodent chow daily, buprenorphine wer  discontinued 
after the 24 h. The site of insertion was examined for 48 h following surgery, quantity of 
food consumed was monitored for a week following surgery to observe any sig s of 
malaise and the animals were weighed weekly until the day of sacrifice. Any animal that 
demonstrated either hematoma formation at the wound site, lack of weightbearing on the 
operated leg after 24 hours or lack of appetite with associated weight loss were 
immediately euthanized.  
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Tissue harvesting:  
Rat femurs, both operated and unoperated, were harvested 1, 4 and 8 weeks 
following implantation of the Ti wires. Animals were anesthetized with pentobarbital 
sodium administered intraperitoneally at the dose of 110 mg/kg and perfused via the 
cardiac aorta with 1X Phosphate buffered Saline (PBS) (for electron microscopy) or with 
1X phosphate buffered saline (PBS) followed by buffered-formalin fixative (for Masson-
Goldner and TRAP staining). The operated femurs were harvested with implants inside 
them and dissected free of soft tissue and muscle. Th  position of all implants was 
verified by radiological analysis and it was observed that none of the implants traversed 
past the mid-diaphysis region (Fig. 1). Those animals whose implants weren’t inserted 
inside the femoral shaft were omitted for the purpose of experimental analysis. Based on 
the radiological location of the implant, a Dremel drill with a rotating bit was used to 
approximately generate three equal sized transverse fragments of the femoral region that 
encompassed the implant while the implant was simultaneously removed. For the purpose 
of analysis, the resulting fragments; A, B and C, were labeled progressing from the 
proximal end of the mid-shaft region towards the distal epiphysis. This systematic 
sectioning technique assured that the sectioned bone area was representative of the entire 
length of the inserted implant. Masson-goldner, toluidine blue followed by electron 
microscopy and TRAP staining were performed on bone specimens to xamine the bone-
implant interface and determine osteoclast numbers respectively.  
Masson- Goldner trichrome staining: 
 Bone specimens A, B and C from each leg of each animal were fixed in 10% 
buffered formalin for 24 h at 4°C, were placed in 70% ethanol until dehydration, trimmed 
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at the ends, dehydrated and embedded in methyl methacrylate as described previously 
(22). Briefly, specimens were dehydrated in 95% and 100% ethanol and embedded in a 
final working solution of 85% methyl methacrylate, 10% glycol methacryl te, 5% dibutyl 
phthalate and 5% (w/v) polyethylene glycol. Undecalcified sections perpendicular to the 
long axis of the bone shaft were cut 5 µm from the distal end of each embedded bone 
block using a Leica microtome, collected in tissue culture plates and stained as described 
previously (19). Sections were flattened using a drop of distilled water and stained for 7 
min using a 1:1 Harris hematoxylin: Ferric chloride mixture soluti n (1.25 g of 
Hematoxylin in 100 ml of 25% Ethanol: 2.5 g Ferric Chloride in 1 ml of C ncentrated 
HCl and 99 ml of distilled water). The stain was removed, sections rinsed twice with 
warm tap water and incubated in 2:1 Ponceau deoxylidine-acid fuchsin staining solution 
(1 g of Ponceau deoxylidine in 1 ml of glacial acetic acid in 100 ml of distilled water: 1 
gm of acid fuchsin in 1 ml of glacial acetic acid in 100 ml of distilled water) for 5 min. 
The stain was removed and sections rinsed with 1% acetic acid. 1% Phosphomolybdic 
acid solution was applied for 6 min, stain removed and rinsed with 1% acetic acid. 
Sections were stained with light green staining solution (0.15 g Light Green Yellowish 
SF in 0.2 ml glacial acetic acid in 100 ml of distilled water) for 2 min, de-stained and 
rinsed twice with 1% acetic acid. Sections were dried on bibulous paper overnight, rinsed 
in 2% ethanol in xylene to clear and soften and mounted using Permount solution.  All 
reagents were obtained from Sigma Aldrich Co. The stained sections were evaluated and 
scored in a blinded manner for different parameters adapted from a previous report by 
Jansen et al. (28) (Table 1). Specifically, qualitative parameters related to bone reparative 
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process such as presence of inflammation, woven bone (immature), lamellar bone 
(mature) and soft tissue fibrosis were noted.  
Tartrate- resistant acid phosphatase (TRAP) staining: 
 Bone specimens A, B and C from each leg of each animal were fixed in 10% 
buffered formalin for 24 h at 4°C, were placed in 70% ethanol until dehydration, trimmed 
at the ends, dehydrated and embedded in methyl methacrylate as described previously 
(22). Briefly, specimens were dehydrated in 95% and 100% ethanol and embedded in a 
final working solution of 85% methyl methacrylate, 10% glycol methacryl te, 5% dibutyl 
phthalate and 5% (w/v) polyethylene glycol. Undecalcified sections perpendicular to the 
long axis of the bone shaft were cut 5 µm from the distal end of each embedded bone 
block using a Leica microtome, collected in tissue culture plates and stained as described 
previously (21). 1 ml of pararosaniline solution was added to sodium nitrite solution (60 
mg of sodium nitrite in 1 ml of water). Twenty five ml of sodium acetate working buffer 
was added to the above solution and pH was adjusted to 5.0 using NaOH. Napthol AS-
TR phosphate solution (1 mg of Naphthol AS-TR phosphate dissolved in 2 ml of N-N-
dimethylformamide) was added to the former solution along with 1 ml of sodium tartrate 
and 10 drops of 10% MnCl2 to make the substrate solution. Sections were stained with 
this substrate solution for 1 h at 37°C and rinsed with distilled water. Counterstaining was 
achieved by incubating sections for 1 min in the following solution: 1 part of 3.9 ml 
working thionin (5.5 mg thionin in 42 ml water) and 1.2 ml working methyl green (0.1 g 
Methyl green in 100 ml water) mixed with 13.5 ml 0.02 M citrate buffer (15 ml of 
solution A [4.2 g of citric acid in 1 L distilled water] and 85 ml of solution B [5.9 ml of 
sodium citrate in 1 L distilled water]) solution mixed with 4 parts of 0.02 M citrate 
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buffer). Sections were rinsed with distilled water, dried on bibulous paper overnight, 
rinsed in 2% ethanol in xylene to clear and soften and mounted using Permount 
solution.  All reagents were obtained from Sigma Aldrich Co. TRAP-positive cells on the 
bone surface were visualized via light microscopy as cells containing reddish pink dye 
deposits. The number of TRAP-positive cells was enumerated from different sections in a 
blinded manner by visualizing 5 random fields of view around the implant site with an 
original magnification of 40X objective.   
Transmission electron microscopy:  
Bone specimens A, B and C from each leg of each animal were fixed in 
Karnovsky’s fixative (3% glutaraldehyde, 3% paraformaldehyde, 0.15% CaCl2 in 0.2 
mol/L sodium cacodylate buffer [pH 7.3]) at 4°C for 24 h and then decalcified in Rapid 
Bone Decalcifier solution (American MasterTech Scientific, CA) for 24-48 h (depending 
on the age of the animals). Following decalcification, bone fragments were trimmed at 
each end and three slices were cut from each end such that the interface is more 
maximally exposed compared to the outer cortical bone surface (Fig 1b). The bone 
sections were then rinsed twice in 0.2 M cacodylate buffer (pH 7.6) for 40 sec, post-fixed 
in 2% osmium tetroxide supplemented with 2% ruthenium red in 0.4 M cacodyl te buffer 
(pH 7.6) for 6 min, again rinsed twice in 0.2 M cacodydate buffer (pH 7.6) for 40 sec, 
dehydrated in a series of ethanol (50, 70, 95, 100 and 100%) for 40 sec each and lastly 
embedded in Spurr’s resin as described previously (38). To obtain representative sections 
for examination via electron microscopy, blocks were thick sectioned (0.9 µm) and then 
stained for 2-5 secs in 1% toluidine blue and 1% tetraborate. Following examination of 
the thicked sections via light microscopy, blocks were selected for thinning and ultra thin 
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sections (95 nm) of bone were cut with a diamond knife on an ultramicrotome. Sections 
were collected on thin-bar hexagonal, 200-mesh copper grids and stained for 15 min with 
2% uranylacetate in 25% ethanol followed by 5 min in a modification of Sato’s triple 
lead citrate (1% Pb nitrate, 1% Pb acetate, 1% Pb citrate, 2% Na citrate, 0.72% NaOH) 
and viewed at 60 KV on a Phillips CM10 transmission electron microscope (Phillips, 
Netherlands).   
 
 
 
 
 
 
CHAPTER 15: RESULTS 
 
  
 Ti-Fn and Ti-Fn-SA wires were inserted inside the medullary c vity of rat femurs 
for 1, 4 and 8 weeks. Following reaming, some holes inside the femurs were left empty to 
examine the bone response in the absence of the biomaterial. One femur was operated on 
per animal and the contralateral leg was evaluated as an additional control. Following 
implantation, all animals ambulated normally within 12 h after surgery and were weight-
bearing on the operated leg with no evidence of swelling at the insertion site. However, 
the reaming only animals all developed hematomas at the surgery site within 24 h after 
surgery and had to be euthanized. For the Ti-Fn and Ti-Fn-SA groups, X-rays taken on 
the day of the sacrifice revealed that the implants weren’t inserted inside the majority of 
femurs and those which were implanted successfully were located inside the medullary 
space extending from the distal epiphysis towards the diaphysis (Fig. 1). Amongst the 
inserted implants, some were positioned more prominently in the distal epiphysis-
metaphysis area while the others were lodged more proximally in the metaphysis-
diaphysis area. As indicated in Fig. 1, fragments A, B and C wereobtained from the 
length of the bone that approximately traverses the implant. Sections were obtained from 
each fragment as outlined in Fig. 1 and the interface was observed using Masson- 
Goldner (MG) stain, Toluidine blue (TB) stain and by tranmission electron microscopy 
(TEM). Masson- Goldner discriminates mineralized bone matrix (stains green), immature 
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new matrix or osteoid (stains red), and osteoid seam, the layer between the newly 
deposited bone and mineralized tissue (stains magenta).  
Data presented and discussed here onward are representative of fragment B only. 
Some of the implants that were lodged more distally were not found to be in contact 
within the region that encompasses fragment A and therefore results from this fragment 
were omitted for purpose of analysis. Data interpretation from fragment C, which was 
especially hard to decalcify, was complicated by the presence of native trabecular bone in 
the metaphysis area which couldn’t be delineated from new bone formati n in response 
to the implant. As shown in Fig. 1, this was more prominent a problem in TB and TEM 
data where transverse sections weren’t obtained, which would have offer d the advantage 
of an obvious implant insertion site; hence accurate estimation of new bone around the 
interface site wasn’t possible in this region of bone. Therefore, for the purpose of 
predicting tissue response following implantation, the bone-implant interface was 
examined in fragment B only and the results are presented below. 
A severe inflammatory reaction around the implant would have manifested as 
tissue swelling, exudate formation or redness around the wound site. How ver, none of 
the above signs were observed following surgery or at the time of sacrifice. In addition, 
radiological evidence of inflammation such as periosteal reaction wasn’t detected in any 
of the implanted femurs either. Histologically, an increased influx of neutrophils and 
macrophages, which can be distinguished by multilobed nuclei and TRAP-positive cells 
outside the bone surface, respectively, can be indicative of an inflammatory environment. 
However, following examination of the implant interface in the Goldner-stained sections, 
such an exacerbated influx of inflammatory cells wasn’t detect d. The resident cells in 
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the implant interface appeared to be mostly fibroblasts, osteoblasts, o eocytes, 
osteoclasts or possibly, osteoprogenitor cells of mesenchymal origin (Figs. 2-6, 9).  
1 week data: 
 By week 1, there was evidence of mineralized woven bone formation arou d the 
implant site in both Ti-Fn and Ti-Fn-SA groups as observed by Masson- Goldner stain 
(Fig. 2). These bone spicules consisted of mineralized matrix lined by osteoid seams 
which were in contact with cuboidal osteoblasts. The formation of bone in both cases 
proceeded from the endosteal cortex surface towards the center of th  medullary cavity. 
Formation of a fibrous tissue layer interposed between the woven bone and the implant 
surface was also observed in both Ti-Fn and Ti-Fn-SA femurs, albeitthicker in the latter 
group. The toluidine blue stained sections along with TEM confirmed the pres nc  of 
woven bony spicules as characterized by the extensive presence of both osteocyte lacunae 
and osteoblasts (Figs. 3 and 4). As demonstrated in Figs. 3b and 4b, fibrous tissue 
formation (1-3 spindle shaped elongated cell layers in thickness) was evident around the 
Ti-Fn insertion site, while a fibrotic 2-6 cell layer was observed in Ti-Fn-SA femurs, 
respectively. Goldner data obtained was representative from one animal per group while 
Toluidine blue/ electron microscopy data was representative of two animals per group. 
4 week data:  
After 4 weeks within a Ti-Fn implanted femur, more mature lamellar new bone 
formation was observed around the insertion site with an intervening conne tive fibrous 
tissue layer. However, in case of Ti-Fn-SA femur, extensive marrow fibrosis was 
observed in the area adjacent to the implant surface. Extensive ew bone formation of 
woven character with thickened osteoid seams was observed adjacent to the fibrotic 
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tissue away from the implant insertion site (Fig. 5). The fibrot c tissue in the space 
between the implant and the woven bone was filled with a large number of oval or 
spindle shaped cells and lightly stained matrix.  
8 week data: 
 After 8 weeks, trabeculae of mature lamellar bone were observed directly in 
contact with the implant insertion site without an intervening fibrous layer at the interface 
in both Ti-Fn and Ti-Fn-SA femurs. The extent of bone formation was similar in both 
groups (Fig. 6).  
The toluidine blue and electron microscopy data following 4 and 8 weeks of 
implant insertion haven’t been included for purpose of analysis. Some of th  limitations 
associated with these sections were the presence of either necrotic fragments in the bone 
tissue that seemed to result from thermal necrosis while burring, lack of an intact implant 
interface due to method of sectioning employed (Fig. 1), or the presenc  of native 
trabecular bone which confounded the data interpretation.  
Blinded qualitative evaluation of tissue reaction around the implant and bone 
implant interface of Masson- Goldner stained sections was performed using the scoring 
system as outlined in Table 1 and the results are represented graphically in Figs. 7 and 8, 
respectively. The numbers of TRAP-positive osteoclasts were measured in both Ti-Fn 
and Ti-Fn-SA femurs (Fig. 9). The number of osteoclasts was highest in both the implant 
groups following 1 week of implantation compared to 4 and 8 week time points. There 
was no discernable difference in osteoclast numbers between the two groups in 
histological sections obtained at 1 week. However, Ti-Fn-SA demonstrated a slight 
increase in the number of osteoclasts compared to Ti-Fn at both 4 and 8 weeks but a 
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statistically significant difference is hard to predict because of the small sample size in 
each group (n=1).  
For all time points, histological sections of fragment B of contralateral 
unimplanted femurs demonstrated bone marrow next to the cortical bone as is the case in 
the diaphysis area of the long bones (data not shown). Although few TRAP-positive cells 
were observed inside the marrow cavity in the femurs, these cells weren’t in contact with 
a bone surface and therefore weren’t considered to be osteoclasts.  
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CHAPTER 16: DISCUSSION 
 
  
The goal of osseointegration of implants is the achievement of a reliable and 
mechanically stable connection between the living bone and implant surface. For implant 
success, bone-bonding is a key factor which is established by directfo mation of bone 
onto the implant surface. Bone formation on the implant interface involves a complex 
sequence of events that includes the recruitment of precursor cells, differentiation of bone 
cells, production of bone matrix and remodeling of the formed bone. Having 
demonstrated enhanced osteoblast functions on Ti-Fn-SA surfaces in vitro, we 
investigated the in vivo use of UV-killed Staphylococcus aureus as a bioactive-coating 
for implant materials in this study.  
The portion of rat bone we have focused our results on is fragment B (Fig. 1), the 
midshaft region of the femur, as in this location any new bone formed would be in 
response to the implant only. The implant interface was observed histolog cally using 
Masson- Goldner trichrome, Toluidine blue staining and Transmission electron 
microscopy. TRAP staining was also done on the sections to determine osteoclast 
numbers. The histologic sections of the implant interface did not reveal any distinct signs 
of inflammation consistent with lack of any visible inflammatory signs at the implant 
insertion site. Particularly, apart from the cell types normally found in bone (osteoblasts, 
osteoclasts and osteocytes), no differences in extent of infiltrating inflammatory cells 
(neutrophils, macrophages) were observed between Ti-Fn and Ti-Fn-SA sections. At all 
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time points, we never detected cartilage and found evidence of new bone formation in 
fragment B (Figs. 2-6). Thus the bone healing seemed to occur exclusively through 
intramembraneous ossification which is believed to be the form of bone repair that occurs 
following implant fixation (11, 14, 40). 
After 1 week, formation of both fibrous tissue and woven bone were prominent 
findings. The fibrous tissue was thicker in case of Ti-Fn-SA implants. The marrow cavity 
in both groups was filled with osteoid and mineralized matrix (Fig. 2). Toluidine blue and 
electron microscopy corroborated the results obtained from Goldner staining (Figs. 3, 4). 
The increased number of TRAP-positive osteoclasts along with woven bone o served 
within 1 week of implant insertion supports that bone resorption and formati n occur 
concomitantly, which is consistent with the findings in other studies (27). Titanium is 
known to act as an inert yet well tolerated metal in bone and very often induces fibrous 
tissue formation around itself which is believed to limit the inflammatory response. After 
4 weeks, a more extensive fibrous tissue layer (about 4-5 cell lay r thick) was observed 
around Ti-Fn-SA implant compared to a thinner soft tissue layer next to the Ti-Fn 
implant surface. In addition, the bone formed around the Ti-Fn interface h d a lamellar 
appearance compared to a more woven bone character with especially wide osteoid 
seams around the Ti-Fn-SA interface. The thick fibrous capsule around the Ti-Fn-SA 
implant may be especially rich in mesenchymal progenitor cells which could differentiate 
into either osteoblasts or fibroblasts. Cells surrounding the implant are believed to 
assume a fibroblastic phenotype if the space surrounding the implants co sists of 
particles smaller than 125µm (10). It is possible that that while ‘press-fitting’ these 
implants, some bacteria, whose diameter would be in the order of microns, may have 
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been released into the surrounding site and favored the formation of the fibrous tissue 
immediate to the implant site. The high density of progenitor cells present inside the 
fibrous tissue or migrated from the endosteal surface explains the continued formation of 
woven bone in Ti-Fn-SA animal group following 4 weeks of insertion. While such 
hypercellularity can result in rapid deposition of osteoid, the rat of mineralization may 
not correlate with the former which could explain the occurrence of the wide osteoid 
seams in Ti-Fn-SA group at 4 weeks (Fig. 5). However, in case of Ti-Fn group, woven 
bone formed earlier appears to have been resorbed and replaced by lamellar bone (Fig. 6). 
After 8 weeks, both Ti-Fn and Ti-Fn-SA femora showed lamellar boneformation directly 
in contact with the implant surface. The osteoclast numbers at this time point had 
decreased, suggesting that bone formation and resorption had balanced sufficiently for 
the maintainance of normal bone structure. The phase between 1 and 8 weeks could be 
the healing period related to the removal of injured tissue at the in erface and stabilizing 
the implant inside the bone.   
A striking parallel exists between the phases of bone repair obseved here and the 
cascade of events that occurs following marrow depletion injury inside long bones. In 
both, infiltration of mesenchymal cells, their differentiation into osteoblasts and 
osteoblast proliferation, formation of woven osteoid and calcification of this woven bone 
matrix, induction of lamellar bone formation in the marrow are observed. This is 
followed by a period of bone remodeling, during which bone resorption occurs before 
regeneration of bone marrow in case of marrow ablation, whereas in the case of implant 
insertion, some bone may still be left in contact with the implant following bone 
resorption (2, 4, 14, 27). The mechanical role of the residual bone is to transmit the load 
 91
from implant to the skeleton. The woven bone that appears in response to the injury is 
believed to be produced by endosteal osteoblasts or osteoblasts derived from progenitor 
stem cells inside the hematopoietic tissue (27). However, these evnts are influenced by 
the environment of the wound area and hence, also by the surface of th  implant. 
Depending on the implant site, other environmental factors determine wh ther 
mesenchymal cells differentiate into fibroblasts, osteoblasts or ch ndrocytes. It is 
possible that the first osteoblasts to arrive at the biomaterial interface may secrete soluble 
or insoluble factors that can recruit more osteoblasts in the vicinity which can explain the 
intense proliferation observed. Some of these factors include local osteoinductive factors 
such as bone morphogenic protein (BMP) and other growth factors such a  Transforming 
growth factor (TGF), Fibroblast growth factor (FGF), and insulin-like growth factor 
(IGF)  which can stimulate osseous proliferation, differentiation and extracellular matrix 
synthesis (42).  
Compared to our in vitro data which demonstrated increased osteoblast functions 
on Ti-Fn-SA versus Ti-Fn surfaces, we didn’t observe as dramatic an effect following 
implant insertion in femurs. In vitro models are more static compared to the dynamic 
environment the implant is exposed to in vivo. Some of the additional variables in vivo 
include implant design, device load, interaction of different cell types, exposure to 
biological fluids such as serum etc. In addition, given the small sample sizes of our in 
vivo groups and other important considerations such as dose of bacteria in the coating 
and method of delivery, which may be critical but not easy to control, neutral findings 
associated with use of killed S. aureus need to be interpreted with caution before it is 
concluded that a given approach lacks utility. For instance, we propose that the available 
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surface area and therefore amount of adherent bacteria on the implant surfaces may 
account for the difference in trends between the in vitro and in vivo responses. The 
surface area of the implant available for bacterial binding was much less in vivo 
compared to in vitro. As a result, the implant surface on the thin Ti wire inserted inside 
the femur may not have been as saturated with bacteria as it w on the in vitro surface, 
whereby the initial adhesion step, which was much enhanced in vitro, may be 
compromised in vivo and may lead to decreased osteoblast binding and a subsequent 
decrease in bone apposition around the implant surface. When we enumerated the 
numbers of live bacteria bound on the implant surface coated under similar conditions as 
the UV-killed bacteria, we found almost a four-log drop in the numbers of bacteria 
compared to the highest possible dose of bound bacteria observed in vitro. Also, given 
that the implants were ‘press-fitted’ into the medullary cavity after reaming, the shear 
stress involved in inserting the implant may be more than sufficient to dislodge the 
bacteria from the implant and deposit them in the dead space between the implant and 
bone thereby initiating undesired responses. As a result, the bacteria were most likely 
engulfed by fibrous tissue to occlude it which can also explain the incr ased thickness of 
fibrous layer in Ti-Fn-SA implants compared to Ti-Fn only following 1 and 4 weeks of 
implantation. The dislodged bacteria may create an insulating barrier ound the implant 
at 4 weeks which may prevent the direct apposition of bone around the implant. 
Assuming that bone deposition on implant entails that osteoblasts first be in the vicinity 
of implant surface, it is understandable that unless the insulating barrier of fibrous tissue 
be cleared, apposition of osteoblasts and subsequent bone deposition will notcommence. 
We therefore conclude that the Ti-Fn-SA implants failed at the Ti-SA interface instead of 
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at bone-implant interface and postulate that a more appropriate presentation of bacteria 
on the prosthesis would result in improved direct bone-implant contact.  
The qualitative examination of a few histological sections as report d in this study 
permits no assessment of osseointegration from a mechanical standpoint between the Ti-
Fn and Ti-Fn-SA groups. Although the bone-implant contact isn’t significa tly different 
among the two groups, the pull out strength of the Ti-Fn-SA implant was much higher 
than Ti-Fn alone among three of the animals tested as evaluated in  blinded fashion. The 
results of some studies indicate that the percentage of surface coverage of implant with 
bone is not as sensitive an indicator of osseintegration as mechanical tests are (13, 45). 
Specifically, implants which had higher pull out strengths did not necessarily show 
increased bone coverage or bone-implant contact compared to groups that were less 
integrated in the tissue. This poor correlation between the effect o  the coating and on 
bone-implant contact suggests that there may be other parameters that might be critical 
such as more bone ingrowth in the nanometric pits of the Ti-Fn surface coated with 
bacteria which could generate more potent bone interlocking at the implant interface (13). 
It is therefore likely that S. aureus coating did have a mechanical effect, but that it simply 
was not detectable as these pits are under the resolution power of th  techniques utilized 
in this study. It is essential to conduct pull out tests in future st dies so as to measure the 
mechanical fixation of the implant which is an important consideration to evaluate the 
functional competence of the regenerated bone.  
The fact that there wasn’t a marked difference in bone formation between the Ti-
Fn and Ti-Fn-SA surfaces may also likely be due to our smooth implant model which 
doesn’t offer as much surface area for bony interlock. This issue can be overcome in 
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future studies by either ‘roughening’ the surface texture by sandblsting/ acid etching the 
Ti surface or by using threaded implant designs before coating with bacteria. Increasing 
roughness creates more surface area for interdigitation of bone which leads to more pull 
out force.  
In the course of this pilot study, we made other observations that would contribute 
towards an improved animal model in the future. For instance, in somet luidine blue 
stained sections, we observed tissue fragments that appeared to be an artifact as a result 
of thermal necrosis following high speed drilling (data not shown). Irrigating the 
medullary cavity with cold saline before implant insertion can reduc  the thermal injury 
and also flush out bone debris generated during the drilling process itself. It is also crucial 
when making histologic and morphometric measurements in bone that the smpling sites 
are accurate in all groups and the sections be obtained in the appropriate plane with no 
obliquity. 
In the chosen rodent model, bone activity changes in response to the implant were 
confounded greatly by bone formation associated with endochondral ossification that 
invariably accompanies growth cartilage activity in the epiphysis during normal 
elongation of long bones in rats. This observation was especially prevalent in fragment C 
and was therefore excluded for the purpose of data analysis. For future studies, we 
recommend using animal models with fused epiphysis as they would retain bone 
remodeling without bone elongation. In the case of rats, growth plate cartilages close 
earlier in females than in males, such that bone elongation ceases at an age where useful 
experimental time for implant studies still remains (29). Using animal models with fused 
epiphysis in conjunction with a fluorochrome label as a marker for bone formation will 
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clearly demonstrate the extent and rate of new bone deposition. In this regard, 
tetracycline labeling is a commonly used fluorochrome that binds to calcium exclusively 
on newly mineralizing bone surfaces. By administering different colored tetracyclines at 
various times during the duration of study and before sacrifice, rat  of new bone 
formation can be measured (20). 
In contrast to the implant groups, our reaming only group demonstrated 
hematoma formation at the surgery site and animals were moribund following surgery. It 
is possible that the access hole in the reaming groups may not have been small enough to 
enable the control of bleeding by mere closure of the skin incision and the debris 
resulting from the drilling may have potentiated the inflammatory response at the site. 
Preliminary data have indicated that it is possible to subvert this problem in the future by 
cauterizing the blood vessels in the medullary canal to stem the bleeding. In case of Ti-Fn 
and Ti-Fn-SA groups, the process of inserting the implant inside the drilled cavity may 
have eliminated some debris and also served to plug the influx of excess fluids. The 
contralateral unoperated leg showed no signs of bone remodeling in the diap ysis region 
at any times thus indicating that the factors released during injury on the operated leg had 
only local and not systemic effects. 
In this context of an animal model with inherent limitations, the most remarkable 
in vivo observation of this pilot study was the stimulation of new bone frmation around 
the Ti-Fn-SA implant, i.e, the osteoconductiveness of the implant. Clearly, more rigorous 
in vivo studies and mechanical testing with greater sample sizes must be carried out 
before recommending this material for hard tissue implant applications. In summary, this 
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preliminary study indicates that Ti-Fn-SA has the potential as a candidate implant 
coating. 
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                                                                                 FIGURES 
 
Figure 1. Schematic diagram of implant insertion and tissue sectioning for histological 
staining and electron microscopy analysis.  
 
 
Table 1. Histologic scoring system for bone reaction around the implant and tissue 
formation at the implant interface as observed on Masson- Goldner stained sections 
following 1, 4 and 8 weeks of insertion. 
Reaction zone Response Score 
Tissue reaction around the implant Similar to original bone 5
Lamellar or woven bone with bone forming activity 4
Lamellar or woven bone with bone forming and osteoclastic activity 3
Other tissue than bone (e.g., fibrous tissue) 2
Inflammation 1
Bone- implant interface Direct bone- implant contact without intervening soft tissue 5
Remodelizing lacuna with osteoblasts and/or osteoclasts on surface 4
Localized fibrous tissue not arranged as capsule 3
Thick fibrous tissue capsule 2
Inflammation 1
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Figure 2. Masson- Goldner staining of bone surrounding the implant site following 1 
week of insertion in the medullary cavity of rat femur (10X). a) Ti-Fn implant; b) Ti-Fn-
SA implant; Implant site, IS; Fibrous tissue, FT; Woven bone, WB. 
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Figure 3. a) Toluidine blue staining of bone surrounding the Ti-Fn implant site following 
4 weeks of insertion in the medullary cavity of rat femur (20X). b) Tranmission electron 
micrograph of fibrous tissue observed at the implant interface (1950X) c) Tranmission 
electron micrograph of woven bone observed around the implant (1950X). Implant site, 
IS; Fibrous tissue, FT; Woven bone, WB; Fibroblast, Fib; Osteocyte, Ost. 
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Figure 4. a) Toluidine blue staining of bone surrounding the Ti-Fn-SA implant site 
following 1 week of insertion in the medullary cavity of rat femur (20X). b) Tranmission 
electron micrograph of fibrous tissue observed at the implant interface (1950X) c) 
Tranmission electron micrograph of woven bone observed around the implant (1950X). 
Implant site, IS; Fibrous tissue, FT; Woven bone, WB; Fibroblast, Fib; Osteocyte, Ost. 
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Figure 5. Masson- Goldner staining of bone surrounding the implant site following 4 
weeks of insertion in the medullary cavity of rat femur (10X). a) Ti-Fn implant; b) Ti-Fn-
SA; Implant site, IS; Fibrous tissue, FT; Woven bone, WB; Lamellar bone, LB; Osteoid 
seam, OS. 
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Figure 6. Masson- Goldner staining of bone surrounding the implant site following 8 
weeks of insertion in the medullary cavity of rat femur (10X). a) Ti-Fn implant; b) Ti-Fn-
SA Implant site, IS; Lamellar bone, LB. 
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Figure 7. Histologic scoring system for bone reaction around Ti-Fn and Ti-Fn-SA 
implant surface as observed on Masson- Goldner stained sections following 1, 4 and 8 
weeks of insertion. 
 
 
Figure 8. Histologic scoring system for tissue reaction around Ti-Fn and Ti-Fn-SA 
implant interface as observed on Masson- Goldner stained sections following 1, 4 and 8 
weeks of insertion. 
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Figure 9. Tartrate-resistant acid phosphatase (TRAP) staining of osteoclasts in bone 
surrounding the implant site following 1, 4 and 8 weeks of insertion in the medullary 
cavity of rat femur.   
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SUMMARY 
 
 
 This dissertation is a compilation of experiments that investigated the responses 
of osteoblasts following S. aureus infection as well as the therapeutic use of nanoparticles 
loaded with antibiotic to target intracellular and extracellular b cteria. Finally we 
examined whether UV-killed S. aureus could act as an osteoconductive coating on bone-
associated biomaterials. 
By determining that RANK-L and PGE2 are up-regulated in osteoblasts infected 
by S. aureus, we have identified possible key molecules involved in the bone destruction 
observed during osteomyelitis. We have also observed that there are PGE2 - independent 
pathway(s) responsible for RANK-L induction in infected osteoblasts. Data demonstrate 
that all formulations of PLGA particles loaded with the antibiotic nafcillin either killed or 
significantly reduced all viable intracellular S. aureus. The use of the data obtained by 
this study and future investigations of the molecular pathways involved in S. aureus-
induced osteomyelitis can result in more effective, alternative treatments for 
osteomyelitis. UV-killed S. aureus is indeed a bioactive coating on bone- associated 
biomaterials both in vivo and in vitro. Osteoblast attachment and adhesion were enhanced 
on titanium alloy surfaces coated with bacteria compared to unc ated surfaces. Cell 
proliferation was sustained at comparable levels in the presence and absence of S. aureus 
while markers of osteoblast differentiation such as collagen synthesis, osteocalcin 
synthesis, alkaline phosphatase activity and mineralized nodule formati n were increased 
on Ti alloy coated with S. aureus compared to uncoated control surfaces. In vivo results 
showed no significant inflammatory response resulting from implants coated with S. 
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aureus and preliminary results suggest that the osteoconductivites of S. aureus-coated 
and uncoated implants were comparable at 8 weeks post-operation. 
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